A Phase 3 interventional study of Lacosamide Tablet and Lacosamide Oral Solution in Epilepsy, sponsored by UCB BIOSCIENCES, Inc.. Completed at 87 sites in 21 countries. Open to participants aged 4 Years and older. Per ClinicalTrials.gov, last updated 2023-12-14.
Sponsored by UCB BIOSCIENCES, Inc. (part of UCB S.A.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies in Epilepsy, Idiopathic Generalized with a site in United States — 2 open to participants now, 2 under way, none of them phase 3. Epilepsy, Idiopathic Generalized · United States.
Among the 17 studies in Epilepsy, Idiopathic Generalized with a site in United States, this one is the 3rd largest by enrollment of the 14 interventional ones that give a count, is one of 2 that started in 2015, is one of 4 in phase 3, and was the 7th registered.
35 studies on the registry are indexed under Epilepsy, Idiopathic Generalized; 4 are open to participants now.
Browse Epilepsy, Idiopathic Generalized studies →2 of the 17 studies in Epilepsy, Idiopathic Generalized with a site in United States are open now. Recruiting first, the newest first:
Praxis Precision Medicines · Sites in United States, Australia, Spain
Ages 18–75
Oregon Health and Science University · Sites in United States
Ages 18–89
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 3 Epilepsy, Idiopathic Generalized studies recruiting now, none set no upper age limit and 3 stop at 75 or younger; 1 takes children under 18; none take healthy volunteers.
This study: 4 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 5 · Phase 3 5 · Phase 4 2
First in 2005; this study’s year is marked. 2 started in 2015.
This study's enrollment of 239 is above the median of 71 across 26 interventional studies indexed under Epilepsy, Idiopathic Generalized.
Median enrollment 61 across the 14 interventional studies, 316 across the 3 observational. Of the 15 that completed or were terminated, 8 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 17 have an industry lead sponsor. The 10 most frequent:
This study is registered under UCB BIOSCIENCES, Inc., one of the names counted as UCB S.A.. Under that name alone:
UCB BIOSCIENCES, Inc. is the lead sponsor of 29 studies on the registry; 2 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 3 (60%) have results posted.
UCB S.A. has 6 studies filed under Epilepsy, Idiopathic Generalized — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 17 studies in Epilepsy, Idiopathic Generalized with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Assessment of long-term safety and efficacy of oral lacosamide (LCM) as an adjunctive therapy for uncontrolled primary generalized tonic-clonic seizures (PGTCS) in subjects >= 4 years of age with idiopathic generalized epilepsy (IGE). This study will enroll subjects from the LCM SP0982 [NCT02408523] study.
35 studies on the registry are indexed under Epilepsy, Idiopathic Generalized; 4 are open to participants now.
This study's enrollment of 239 is above the median of 71 across 26 interventional studies indexed under Epilepsy, Idiopathic Generalized.
Browse Epilepsy, Idiopathic Generalized studies →UCB BIOSCIENCES, Inc. is the lead sponsor of 29 studies on the registry; 2 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 3 (60%) have results posted.
Compared within Epilepsy, Idiopathic Generalized, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Epilepsy. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Start dose SP0982 completers at V1: * LCM 10 mg/kg/day for pediatric subjects weighing \<30 kg * LCM 8 mg/kg/day for pediatric subjects weighing ≥ 30kg to \<50 kg * LCM 400 mg/day (200 mg bid) for adult subjects (≥18 years of age) or pediatric subjects weighing ≥50 kg SP0982 Baseline failures at V1: * LCM 2 mg/kg/day for pediatric subjects weighing \<50 kg * LCM 100 mg/day (50 mg bid) for adult subjects (≥18 years of age) or pediatric subjects weighing ≥50 kg Oral solution (pediatric subjects \<50 kg): * Minimum LCM dose: 4 mg/kg/day * Maximum LCM dose: 12 mg/kg/day Tablets (pediatric subjects ≥50kg): * Minimum LCM dose: 200 mg/day * Minimum LCM dose: 600 mg/day Tablets (adult subjects): * Minimum LCM dose: 200 mg/day * Maximum LCM dose: 800 mg/day
Drug: Lacosamide Tablet · Drug: Lacosamide Oral Solution
* Active substance: Lacosamide * Pharmaceutical form: Tablet * Concentration: 50 mg and 100 mg * Route of Administration: Oral administration
Also known as: Vimpat, LCM
* Active substance: Lacosamide * Pharmaceutical form: Oral solution * Concentration: 10 mg/ml * Route of Administration: Oral administration
Also known as: Vimpat, LCM
Number of Study Participants With Treatment-emergent Adverse Events (TEAEs) Over the Duration of the Treatment Period
AEs were considered treatment-emergent if event had onset on or after date of first study medication dose in EP0012 and within 30 days following last study medication dose or events whose intensity worsened on or after date of first study medication dose and within 30 days following date of last study medication administration. Adverse Events were reported spontaneously by the participant and/or caregiver or observed by the investigator.
Time frame: From Visit 1 (Week 0) to End of Treatment Period (up to approximately 5 years)
Number of Study Participants Withdrawn Due to TEAEs
AEs were considered treatment-emergent if event had onset on or after date of first study medication dose in EP0012 and within 30 days following last study medication dose or events whose intensity worsened on or after date of first study medication dose and within 30 days following date of last study medication administration. Adverse Events were reported spontaneously by the participant and/or caregiver or observed by the investigator.
Time frame: From Visit 1 (Week 0) to End of Treatment Period (up to approximately 5 years)
Number of Study Participants With New Appearance of Absence and/or Myoclonic Seizures During the Treatment Period
The number of study participants with appearance of new absence and/or myoclonic seizure types experienced during the Treatment Period but who did not experience in Combined Baseline Period or in seizure classification history, before taking LCM were reported. To determine appearance of new seizure type, the Combined Baseline Period was used. Thus, the participants who directly enrolled into EP0012, the Baseline absence, and/or myoclonic seizure data from SP0982's 4-week Prospective Baseline Period were combined with any reported Baseline absence, and myoclonic seizure information in the daily seizure diary from EP0012 (reported before first dose in EP0012) to recalculate the study participant's Baseline variables such as days with absence, and/or myoclonic seizures per 28 days.
Time frame: From Visit 1 (Week 0) to End of Treatment Period (up to approximately 5 years)
Number of Study Participants With an Increase of up to 25% in Days With Absence Seizures Per 28 Days During the Treatment Period as Compared to the Prospective Baseline (of Study SP0982)
The number of participants experiencing an increase of up to 25% in the number of days with absence seizures per 28 days during the Treatment Period compared to the Prospective Baseline Period (for those participants with absence seizure data reported in the 4-week Prospective Baseline Period in SP0982) were reported. This period started on the day of Visit 1 of SP0982 and ended the day before Visit 2 of SP0982. For the direct enrollers into EP0012, Prospective Baseline ended the day before Visit 1 (or prior to first dose) of EP0012.
Time frame: From Visit 1 (Week 0) to End of Treatment Period (up to approximately 5 years), compared to the Prospective SP0982 Baseline Period
Number of Study Participants With an Increase of Greater Than (>)25% to 50% in Days With Absence Seizures Per 28 Days During the Treatment Period as Compared to the Prospective Baseline (of Study SP0982)
The number of participants experiencing an increase of \>25% to 50% in the number of days with absence seizures per 28 days during the Treatment Period compared to the Prospective Baseline Period (for those participants with absence seizure data reported in the 4-week Prospective Baseline Period in SP0982) were reported. This period started on the day of Visit 1 of SP0982 and ended the day before Visit 2 of SP0982. For the direct enrollers into EP0012, Prospective Baseline ended the day before Visit 1 (or prior to first dose) of EP0012.
Time frame: From Visit 1 (Week 0) to End of Treatment Period (up to approximately 5 years), compared to the Prospective SP0982 Baseline Period
Number of Study Participants With an Increase of >50% to 75% in Days With Absence Seizures Per 28 Days During the Treatment Period as Compared to the Prospective Baseline (of Study SP0982)
The number of participants experiencing an increase of \>50% to 75% in the number of days with absence seizures per 28 days during the Treatment Period compared to the Prospective Baseline Period (for those participants with absence seizure data reported in the 4-week Prospective Baseline Period in SP0982) were reported. This period started on the day of Visit 1 of SP0982 and ended the day before Visit 2 of SP0982. For the direct enrollers into EP0012, Prospective Baseline ended the day before Visit 1 (or prior to first dose) of EP0012.
Time frame: From Visit 1 (Week 0) to End of Treatment Period (up to approximately 5 years), compared to the Prospective SP0982 Baseline Period
Number of Study Participants With an Increase of >75% in Days With Absence Seizures Per 28 Days During the Treatment Period as Compared to the Prospective Baseline (of Study SP0982)
The number of participants experiencing an increase of \>75% in the number of days with absence seizures per 28 days during the Treatment Period compared to the Prospective Baseline Period (for those participants with absence seizure data reported in the 4-week Prospective Baseline Period in SP0982) were reported. This period started on the day of Visit 1 of SP0982 and ended the day before Visit 2 of SP0982. For the direct enrollers into EP0012, Prospective Baseline ended the day before Visit 1 (or prior to first dose) of EP0012.
Time frame: From Visit 1 (Week 0) to End of Treatment Period (up to approximately 5 years), compared to the Prospective SP0982 Baseline Period
Number of Study Participants With an Increase of up to 25% in Days With Myoclonic Seizures Per 28 Days During the Treatment Period as Compared to the Prospective Baseline (of Study SP0982)
The number of participants experiencing an increase of up to 25% in the number of days with myoclonic seizures per 28 days during the Treatment Period compared to the Prospective Baseline Period (for those participants with myoclonic seizure data reported in the 4-week Prospective Baseline Period in SP0982) were reported. This period started on the day of Visit 1 of SP0982 and ended the day before Visit 2 of SP0982. For the direct enrollers into EP0012, Prospective Baseline ended the day before Visit 1 (or prior to first dose) of EP0012.
Time frame: From Visit 1 (Week 0) to End of Treatment Period (up to approximately 5 years), compared to the Prospective SP0982 Baseline Period
Number of Study Participants With an Increase of >25% to 50% in Days With Myoclonic Seizures Per 28 Days During the Treatment Period as Compared to the Prospective Baseline (of Study SP0982)
The number of participants experiencing an increase of \>25% to 50% in the number of days with myoclonic seizures per 28 days during the Treatment Period compared to the Prospective Baseline Period (for those participants with myoclonic seizure data reported in the 4-week Prospective Baseline Period in SP0982) were reported. This period started on the day of Visit 1 of SP0982 and ended the day before Visit 2 of SP0982. For the direct enrollers into EP0012, Prospective Baseline ended the day before Visit 1 (or prior to first dose) of EP0012.
Time frame: From Visit 1 (Week 0) to End of Treatment Period (up to approximately 5 years), compared to the Prospective SP0982 Baseline Period
Number of Study Participants With an Increase of >50% to 75% in Days With Myoclonic Seizures Per 28 Days During the Treatment Period as Compared to the Prospective Baseline (of Study SP0982)
The number of participants experiencing an increase of \>50% to 75% in the number of days with myoclonic seizures per 28 days during the Treatment Period compared to the Prospective Baseline Period (for those participants with myoclonic seizure data reported in the 4-week Prospective Baseline Period in SP0982) were reported. This period started on the day of Visit 1 of SP0982 and ended the day before Visit 2 of SP0982. For the direct enrollers into EP0012, Prospective Baseline ended the day before Visit 1 (or prior to first dose) of EP0012.
Time frame: From Visit 1 (Week 0) to End of Treatment Period (up to approximately 5 years), compared to the Prospective SP0982 Baseline Period
Number of Study Participants With an Increase of >75% in Days With Myoclonic Seizures Per 28 Days During the Treatment Period as Compared to the Prospective Baseline (of Study SP0982)
The number of participants experiencing an increase of \>75% in the number of days with myoclonic seizures per 28 days during the Treatment Period compared to the Prospective Baseline Period (for those participants with myoclonic seizure data reported in the 4-week Prospective Baseline Period in SP0982) were reported. This period started on the day of Visit 1 of SP0982 and ended the day before Visit 2 of SP0982. For the direct enrollers into EP0012, Prospective Baseline ended the day before Visit 1 (or prior to first dose) of EP0012.
Time frame: From Visit 1 (Week 0) to End of Treatment Period (up to approximately 5 years), compared to the Prospective SP0982 Baseline Period
Percentage of Study Participants With at Least 50% Worsening in Days With Absence Seizures
Seizure worsening was defined as a participant experiencing \>=50% increase in the number of days with absence seizures per 28 days from Prospective Baseline. Percentages for seizure worsening were based on those participants who have reported a history of or an occurrence of absence seizures in Prospective Baseline or the Treatment Period.
Time frame: From Visit 1 (Week 0) to End of Treatment Period (up to approximately 5 years)
Percentage of Study Participants With at Least 50% Worsening in Days With Myoclonic Seizures
Seizure worsening was defined as a participant experiencing \>=50% increase in the number of days with myoclonic seizures per 28 days from Prospective Baseline. Percentages for seizure worsening were based on those participants who have reported a history of or an occurrence of myoclonic seizures in Prospective Baseline or the Treatment Period.
Time frame: From Visit 1 (Week 0) to End of Treatment Period (up to approximately 5 years)
Percentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in Hematology Parameters (Hemoglobin)
TEMA values are defined in the Statistical Analysis Plan (SAP) as significant deviations from the expected range of age-appropriate values. TEMA laboratory results of Hematology parameter, Hemoglobin were those that were observed post-Baseline (BL) during the Treatment Period but not present at Baseline. For the age range, '2 years (y) to \<17 years', the abnormality criteria were '\<=95' grams/deciliter (g/dL) (Low) and '\>160' g/dL (High). For age range, '\>=17 years', the abnormality Criteria were '\<=85% of lower limit of normal (LLN)' value (Low) and '\>=115% of upper limit of normal (ULN)' value (High) of Hemoglobin in blood.
Time frame: During the study (up to approximately 5 years)
Percentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in Hematology Parameters (Hematocrit)
TEMA values are defined in the SAP as significant deviations from the expected range of age-appropriate values. TEMA laboratory results of Hematocrit were those that were observed post-BL during the Treatment Period but not present at BL. For the age range, '2 years to \<17 years', the abnormality criteria were '\<=29%' (Low) and '\>47%' (High) hematocrit values. For age range, '\>=17 years', the abnormality criteria were '\<=85% of LLN' (Low) and '\>=115% of ULN' (High) of Hematocrit values in blood.
Time frame: During the study (up to approximately 5 years)
Percentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in Hematology Parameters (Platelets)
TEMA values are defined in the SAP as significant deviations from the expected range of age-appropriate values. TEMA laboratory results of Platelet count were those that were observed post-BL during the Treatment Period but not present at BL. For the age range of '\>1 month', the abnormality criteria were '\<=100' 10\^9/L and '\>=600' 10\^9/L of Platelets count value.
Time frame: During the study (up to approximately 5 years)
Percentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in Hematology Parameters (Erythrocytes)
TEMA values are defined in the SAP as significant deviations from the expected range of age-appropriate values. TEMA laboratory results of Erythrocytes parameter were those that were observed post-BL during the Treatment Period but not present at BL. For the age range, '\>=2years', the abnormality criteria were '\<3.5' 10\^12/L of Erythrocytes value in blood. Early Termination Visit (TV) was last visit in the study (up to approximately 5 years).
Time frame: During the study (up to approximately 5 years)
Percentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in Hematology Parameters (Leukocytes)
TEMA values are defined in the SAP as significant deviations from the expected range of age-appropriate values. TEMA laboratory results of Leukocytes were those that were observed post-BL during the Treatment Period but not present at BL. For all age ranges, the abnormality criteria were '\<=3.0' 10\^9/L (Low) and '\>= 16.0' 10\^9/L (High) of Leukocytes values in blood.
Time frame: During the study (up to approximately 5 years)
Percentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in Hematology Parameters (Basophils Absolute)
TEMA values are defined in the SAP as significant deviations from the expected range of age-appropriate values. TEMA laboratory results of Basophils Absolute were those that were observed post-BL during the Treatment Period but not present at BL. For the age range, '\>1 month', the abnormality criteria were '\>=0.4' 10\^9/L of Basophils in blood.
Time frame: During the study (up to approximately 5 years)
Percentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in Hematology Parameters (Eosinophils Absolute)
TEMA values are defined in the SAP as significant deviations from the expected range of age-appropriate values. TEMA laboratory results of Eosinophils Absolute were those that were observed post-BL during the Treatment Period but not present at BL. For the age range, '\>1 month', the abnormality criteria were '\>=1.0' 10\^9/L of Eosinophils in the blood.
Time frame: During the study (up to approximately 5 years)
Percentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in Hematology Parameters (Lymphocytes Absolute)
TEMA values are defined in the SAP as significant deviations from the expected range of age-appropriate values. TEMA laboratory results of Lymphocytes Absolute were those that were observed post-Baseline (BL) during the Treatment Period but not present at Baseline. For the age range, '2 years - \<6 years', the abnormality criteria were '\<0.7' 10\^9/L (Low) and '\>6.9' 10\^9/L (High). For age range, '\>=6 years', the abnormality criteria were '\<0.6' 10\^9/L (Low) and '\>5.0' 10\^9/L (High) for Lymphocytes Absolute in the blood.
Time frame: During the study (up to approximately 5 years)
Percentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in Hematology Parameters (Monocytes Absolute )
TEMA values are defined in the SAP as significant deviations from the expected range of age-appropriate values. TEMA laboratory results of Monocytes Absolute were those that are observed post-BL during the Treatment Period but not present at BL. For the age range, '\>1 month', the abnormality criteria was '\>=2.0' 10\^9/L of Monocytes in blood.
Time frame: During the study (up to approximately 5 years)
Percentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in Hematology Parameters (Neutrophils Absolute)
TEMA values are defined in the SAP as significant deviations from the expected range of age-appropriate values. TEMA laboratory results of Neutrophils Absolute were those that were observed post-BL during the Treatment Period but not present at BL. For the age range, '\>1 month', the abnormality criteria was '\<1.5' 10\^9/L of Neutrophils in blood.
Time frame: During the study (up to approximately 5 years)
Percentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in Serum Chemistry Parameters (Calcium)
TEMA values are defined in the SAP as significant deviations from the expected range of age-appropriate values. TEMA laboratory results of Calcium were those that were observed post- BL during the Treatment Period but not present at Baseline. For the age range, '1 year -\<17 years', the abnormality criteria were '\<=1.85' millimoles per litre (mmol/L) and '\>=2.95' mmol/L. For age range, '\>=17 years', the abnormality criteria was '\<=1.9 mmol/L' and '\>=2.75 mmol/L' of serum Calcium.
Time frame: During the study (up to approximately 5 years)
Percentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in Serum Chemistry Parameters (Sodium)
TEMA values are defined in the SAP as significant deviations from the expected range of age-appropriate values. TEMA laboratory results of Sodium were those that were observed post- BL during the Treatment Period but not present at Baseline. For the age range, '\>1 month', the abnormality criteria were '\<127' mmol/L (Low) and '\>151' mmol/L (High) of serum Sodium.
Time frame: During the study (up to approximately 5 years)
Percentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in Serum Chemistry Parameters (Potassium)
TEMA values are defined in the SAP as significant deviations from the expected range of age-appropriate values. TEMA laboratory results of Potassium were those that were observed post- BL during the Treatment Period but not present at Baseline. For the age range, '\>=1 year', the abnormality criteria were '\<= 3.0' mmol/L (Low) and '\>= 6.0' mmol/L (High) of serum Potassium.
Time frame: During the study (up to approximately 5 years)
Percentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in Serum Chemistry Parameters (Chloride)
TEMA values are defined in the SAP as significant deviations from the expected range of age-appropriate values. TEMA laboratory results of Chloride were those that were observed post- BL during the Treatment Period but not present at Baseline. For the age range, '\>1 month', the abnormality criteria were '\<=90' mmol/L (Low) and '\>=112' mmol/L (High) of serum Chloride.
Time frame: During the study (up to approximately 5 years)
Percentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in Serum Chemistry Parameters (Bicarbonate)
TEMA values are defined in the SAP as significant deviations from the expected range of age-appropriate values. TEMA laboratory results of Bicarbonate were those that were observed post- BL during the Treatment Period but not present at Baseline. For the age range, '\>1 month-\<17 years', the abnormality criteria were '\<15' mmol/L (Low) and '\>38' mmol/L (High). For age range, '\>=17 years', the abnormality criteria were '\<18' mmol/L (Low) and '\>38' mmol/L (High) of serum Bicarbonate.
Time frame: During the study (up to approximately 5 years)
Percentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in Serum Chemistry Parameters (Creatinine)
TEMA values are defined in the SAP as significant deviations from the expected range of age-appropriate values. TEMA laboratory results of Creatinine were those that were observed post- BL during the Treatment Period but not present at Baseline. For the age range, '1-\<10 years', the abnormality criteria were '\>106.8' micromole per litre (umol/L), for '10-\<16 years', the abnormality criteria were '\>159.12' umol/L and for '\>=16 years', the abnormality criteria was '\>=176.8' umol/L for serum Creatinine.
Time frame: During the study (up to approximately 5 years)
Percentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in Serum Chemistry Parameters (Aspartate Aminotransferase)
TEMA values are defined in the SAP as significant deviations from the expected range of age-appropriate values. TEMA laboratory results of Aspartate Aminotransferase (AST) were those that were observed post- BL during the Treatment Period but not present at Baseline. For all ages, the abnormality criteria were specified as '≥3.0 units per litre (U/L) x ULN' (High A), '≥5.0 U/L x ULN' (High B), and '≥10.0 U/L x ULN' (High C) of serum AST.
Time frame: During the study (up to approximately 5 years)
Percentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in Serum Chemistry Parameters (Alanine Aminotransferase)
TEMA values are defined in the SAP as significant deviations from the expected range of age-appropriate values. TEMA laboratory results of Alanine Aminotransferase (ALT) were those that were observed post- BL during the Treatment Period but not present at Baseline. For all ages, the abnormality criteria were specified as '≥3.0 U/L x ULN' (High A), '≥5.0 U/L x ULN' (High B), and '≥10.0 U/L x ULN' (High C) of serum ALT.
Time frame: During the study (up to approximately 5 years)
Percentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in Chemistry Parameters (Total Bilirubin)
TEMA values are defined in the SAP as significant deviations from the expected range of age-appropriate values. TEMA laboratory results of Total Bilirubin were those that were observed post- BL during the Treatment Period but not present at Baseline. For the age range, '\>1 month', the abnormality criteria was '≥34.208' umol/L of serum Bilirubin.
Time frame: During the study (up to approximately 5 years)
Percentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in Serum Chemistry Parameters (Alkaline Phosphatase)
TEMA values are defined in the SAP as significant deviations from the expected range of age-appropriate values. TEMA laboratory results of Alkaline Phosphatase were those that were observed post- BL during the Treatment Period but not present at Baseline. For the age range, '4 years -\<10 years', the abnormality criteria was '\>=834 U/L', for '10 years -\<17 years', the abnormality criteria was '\>=1761 U/L' and for '\>=17 years', the abnormality criteria was '\>=3.0 U/L x ULN' of serum alkaline phosphatase.
Time frame: During the study (up to approximately 5 years)
Percentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in Serum Chemistry Parameters (Gamma Glutamyl Transferase)
TEMA values are defined in the SAP as significant deviations from the expected range of age-appropriate values. TEMA laboratory results of Gamma Glutamyl Transferase (GGT) were those that were observed post- BL during the Treatment Period but not present at Baseline. For the age range, '1 year-\<13 years', the abnormality criteria was '\>=66' U/L (High A), for '13 years-\<17 years', the abnormality criteria was '\>=126' U/L (High B) and for '\>=17 years', the abnormality criteria was '\>=3.0 U/L x ULN' (High C) of serum GGT.
Time frame: During the study (up to approximately 5 years)
Percentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in Serum Chemistry Parameters (Glucose)
TEMA values are defined in the SAP as significant deviations from the expected range of age-appropriate values. TEMA laboratory results of Glucose were those that were observed post- BL during the Treatment Period but not present at Baseline. For the age range, '\>1 month-\<17 years', the abnormality criteria were from '\<2.775' mmol/L (Low) and '\>=9.99' mmol/L (High). For age range, '\>=17 years', the abnormality criteria were '\<2.775' mmol/L (Low) and '\>=11.1' mmol/L (High) of serum Glucose.
Time frame: During the study (up to approximately 5 years)
Percentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in Serum Chemistry Parameters (Albumin)
TEMA values are defined in the SAP as significant deviations from the expected range of age-appropriate values. TEMA laboratory results of Albumin were those that were observed post- BL during the Treatment Period but not present at Baseline. For the age range, '\>=1 year to \<17 years', the abnormality criteria were '\<24' g/L and '\>84' g/L and for age range, '\>=17 years', the abnormality criteria was '\<26' g/L of serum albumin.
Time frame: During the study (up to approximately 5 years)
Percentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in Serum Chemistry Parameters (Total Protein)
TEMA values are defined in the SAP as significant deviations from the expected range of age-appropriate values. TEMA laboratory results of Total Protein were those that were observed post- BL during the Treatment Period but not present at Baseline. For the age range, '1 year to \<17 years', the abnormality criteria were '\<43' g/L and '\>120' g/L. For age range, '\>=17 years', the abnormality criteria were '\<43' g/L and '\>130' g/L of serum protein.
Time frame: During the study (up to approximately 5 years)
Percentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in Serum Chemistry Parameters (Phosphate)
TEMA values are defined in the SAP as significant deviations from the expected range of age-appropriate values. TEMA laboratory results of Phosphate were those that are observed post- BL during the Treatment Period but not present at Baseline. For the age range, '1 year-\<17 years', the abnormality criteria were from '\<0.5814' mmol/L (Low) and '\>2.3902' mmol/L (High). For age range, '\>=17 years', the abnormality Criteria were '\<=0.646' mmol/L (Low) and '\>=1.938' mmol/L (High) of serum phosphate.
Time frame: During the study (up to approximately 5 years)
Percentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in 12-lead Electrocardiogram (ECG) Parameter (QT Interval)
TEMA values are defined in the SAP as significant deviations from the expected range of age-appropriate values. TEMA ECG results of QT interval parameter were those that were observed post- BL during the Treatment Period but not present at Baseline. For the age range, '1 month (m)-\<12 years', the abnormality criteria were '\>=500 milliseconds (ms)' (Abnormal (Abn) A). For age range, '\>=12 years', the abnormality criteria were '\>=500 ms' (Abn B) or '\>=60 ms increase from Baseline' (Abn C). The abnormality in QT interval was observed at Week 0 as the participant was rolled over from SP0982 study and was constantly having abnormal ECG parameters while in SP0982 and EP0012.
Time frame: During the study (up to approximately 5 years)
Percentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in 12-lead ECG Parameter (QTc(F) Interval)
TEMA values are defined in the SAP as significant deviations from the expected range of age-appropriate values. TEMA ECG results of QTc(F) interval were those that are observed post- BL during the Treatment Period but not present at Baseline. For the age range '3 years -\<12 years' and '\>=12 years- \<17 years', the abnormality criteria were from '\>440 ms' (Abn A) and '\>15% increase from Baseline' value (Abn B). For age range, '\>=17 years', the abnormality Criteria were '\>450 ms' (Abn C), '\>480 ms' (Abn D), '\>500 ms' (Abn E) or '\>=60 ms increase from Baseline' value (Abn F). The abnormality in QTc(F) interval was observed at Week 0 as the participant was rolled over from SP0982 study and was constantly having abnormal ECG parameters while in SP0982 and EP0012.
Time frame: During the study (up to approximately 5 years)
Percentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in 12-lead ECG Parameter (QTc(B) Interval)
TEMA values are defined in the SAP as significant deviations from the expected range of age-appropriate values. TEMA ECG results of QTc(B) interval were those that are observed post- BL during the Treatment Period but not present at Baseline. For the age range '3 years -\<12 years' and '\>=12 years- \<17 years', the abnormality criteria were '\>450 ms' (Abn A) and '\>15% increase from Baseline' value (Abn B). For age range, '\>=17 years', the abnormality criteria were '\>450 ms' (Abn C), '\>480 ms' (Abn D), '\>500 ms' (Abn E) or '\>=60 ms increase from Baseline' value (Abn F). The abnormality in QTc(B) interval was observed at Week 0 as the participant was rolled over from SP0982 study and was constantly having abnormal ECG parameters while in SP0982 and EP0012.
Time frame: During the study (up to approximately 5 years)
Percentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in 12-lead ECG Parameter (PR Interval)
TEMA values are defined in the SAP as significant deviations from the expected range of age-appropriate values. TEMA ECG results of PR interval were those that were observed post- BL during the Treatment Period but not present at Baseline. For the age range, '3 years -\<12 years', the abnormality criteria were '\>180 ms' (Abn A) and '\>25% increase from Baseline' value (Abn B). For the age range, '\>=12 years - \<17 years', the abnormality criteria were '\>200 ms' (Abn C) and '\>25% increase from Baseline' value (Abn D). For age range, '\>=17 years', the abnormality criteria were treatment-emergent values above '\>200 ms' (Abn E), '\>220 ms' (Abn F), or '\>250 ms' (Abn G).
Time frame: During the study (up to approximately 5 years)
Percentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in 12-lead ECG Parameter (QRS Interval)
TEMA values are defined in the SAP as significant deviations from the expected range of age-appropriate values. TEMA ECG results of QRS interval were those that were observed post- BL during the Treatment Period but not present at Baseline. For the age range, '3 years -\<12 years', the abnormality criteria were '\>100 ms' (Abn A) and '\>25% increase from Baseline' value (Abn B). For the age range, '\>=12 years - \<17 years', the abnormality criteria were '\>110 ms' (Abn C) and '\>25% increase from Baseline' (Abn D). For age range, '\>=17 years', the abnormality criteria were treatment-emergent values above '\>100 ms' (Abn E), '\>120 ms' (Abn F), or '\>140 ms' (Abn G).
Time frame: During the study (up to approximately 5 years)
Percentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in 12-lead ECG Parameter (Heart Rate Interval)
TEMA values are defined in the SAP as significant deviations from the expected range of age-appropriate values. TEMA ECG results of Heart rate interval were those that were observed post- BL during the Treatment Period but not present at Baseline. For the age range, '3 years -\<12 years', the abnormality criteria were '\<60 beats per minute (bpm)' (Abn A) and '\>130 bpm' (Abn B). For the age range, '\>=12 years', the abnormality criteria were '\<50 bpm' (Abn C) and '\>120 bpm' (Abn D).
Time frame: During the study (up to approximately 5 years)
Percentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in Vital Sign Measurements (Pulse Rate)
TEMA values are defined in the SAP as significant deviations from the expected range of age-appropriate values. TEMA vital signs results of Pulse rate were those that were observed post- BL during the Treatment Period but not present at Baseline. For the age range, '3 years -\<12 years', the abnormality criteria were '\<60 bpm' (Low) and '\>130 bpm' (High). For the age range, '12 years - \<17 years', the abnormality criteria were '\<=50 bpm' (Low) and '\>=120 bpm' (High). For the age range, '\>=17 years', the abnormality criteria were '\<=50 bpm and a decrease from Baseline of \>=15 bpm' (Low A), '\>=120 bpm and an increase from Baseline of \>=15 bpm' (High A), '\<60 bpm' (Low B) and '\>100 bpm' (High B). The Pulse rate was reported as per positions such as 'Supine 3 minute (Sup 3 min)', 'Standing 1 minute' (Std 1 min), and 'Standing 3 minute' (Std 3 min).
Time frame: During the study (up to approximately 5 years)
Percentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in Vital Sign Measurements (Systolic Blood Pressure)
TEMA values of Systolic Blood Pressure (BP) results were those that were observed post- BL during the Treatment Period but not present at Baseline. For the age range, '3 years -\<12 years', the abnormality criteria were '\<80 millimeters of mercury (mmHg)' (Low) and '\>140 mmHg' (High). For the age range, '\>=12 years - \<17 years', the abnormality criteria were '\<90 mmHg' (Low) and '\>160 mmHg' (High). For the age range, '\>=17 years', the abnormality criteria were '\<=90 mmHg and decrease from Baseline of \>=20 mmHg' (Low A), '\>=180 mmHg and increase from Baseline of \>=20' mmHg (High A), '\<90 mmHg' (Low B), '\>140 mmHg (High B), and '\>160 mmHg' (High C). Systolic BP were reported as per positions such as 'Sup 3 min', 'Std 1 min, and 'Std 3 min'.
Time frame: During the study (up to approximately 5 years)
Percentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in Vital Sign Measurements (Diastolic Blood Pressure)
TEMA values of Diastolic BP results were those that are observed post- BL during the Treatment Period but not present at Baseline. For the age range, '3 years -\<12 years', the abnormality criteria were '\<50 mmHg' (Low) and '\>80 mmHg' (High), '\>=12 years - \<17 years', the abnormality criteria were '\<=50 mmHg' (Low) and '\>=105 mmHg' (High), and '\>=17 years', the abnormality criteria were '\<=50 mmHg and decrease from Baseline of \>=15 mmHg' (Low A), '\>=105 mmHg and increase from Baseline of \>=15' mmHg (High A), '\<50 mmHg' (Low B), '\>90 mmHg' (High B), and '\>100 mmHg' (High C). Diastolic BP were reported as per positions such as 'Sup 3 min', 'Std 1 min, and 'Std 3 min'.
Time frame: During the study (up to approximately 5 years)
Percentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in Vital Sign Measurements (Body Weight)
TEMA values are defined in the SAP as significant deviations from the expected range of age-appropriate values. TEMA vital signs parameter results were those that are observed post- BL during the Treatment Period but not present at Baseline. For the age range, '1 month - \<17 years', the abnormality criteria were '\<3% of normal body weight' in Kilograms (kg) or '\>97% of normal body weight' in kgs. Here, '\<3% of normal' is presented as 'Low' and '\>97% of normal' is presented as 'High'. For the age range '\>=17 years', the abnormality criteria were 'Increase/decrease of \>=10%' body weight in kgs (presented as Inc/Dec A) or 'Increase/decrease of \>=7%' body weight in kgs (presented as Inc/Dec B).
Time frame: During the study (up to approximately 5 years)
Percent Change in Primary Generalized Tonic-clonic Seizure (PGTCS) Frequency Per 28 Days From Combined Baseline
The 28-day PGTCS frequency during the relative period was subtracted from the 28-day Combined Baseline PGTCS frequency and the result was divided by 28-day Combined Baseline PGTCS frequency and the result was then multiplied by 100 to get percent change in PGTCS frequency per 28 days from Combined Baseline Period (CB) to the appropriate analysis Period. The CB was defined as the combined 12-week Historical Baseline and 4-week Prospective Baseline periods immediately prior to randomization in the study SP0982 or prior to Visit 1 (first dose) if direct enrollers in EP0012.
Time frame: From Combined Baseline until end of Treatment Period (up to approximately 5 years)
The study started to enroll participants in August 2015 and concluded in March 2023. Study participants from SP0982 \[NCT02408523\], who met EP0012 eligibility criteria were enrolled.
| Milestone | All Participants (Lacosamide) |
|---|---|
| Started | 239 |
| Completed | 157 |
| Not completed | 82 |
| Withdrew: Adverse event | 15 |
| Withdrew: Death | 4 |
| Withdrew: Lack of efficacy | 17 |
| Withdrew: Protocol violation | 4 |
| Withdrew: Lost to follow-up | 6 |
| Withdrew: Consent withdrawn | 30 |
| Withdrew: Neurology research program closing at site | 1 |
| Withdrew: Site closure | 1 |
| Withdrew: Pregnancy | 1 |
| Withdrew: Withdrawal of consent due to business trip | 1 |
| Withdrew: Subject moved to another place, far from site | 1 |
| Withdrew: Study terminated at site | 1 |
AEs were considered treatment-emergent if event had onset on or after date of first study medication dose in EP0012 and within 30 days following last study medication dose or events whose intensity worsened on or after date of first study medication dose and within 30 days following date of last study medication administration. Adverse Events were reported spontaneously by the participant and/or caregiver or observed by the investigator.
| Participants | All Participants (Lacosamide) |
|---|---|
| Number of Study Participants With Treatment-emergent Adverse Events (TEAEs) Over the Duration of the Treatment Period | 222 |
AEs were considered treatment-emergent if event had onset on or after date of first study medication dose in EP0012 and within 30 days following last study medication dose or events whose intensity worsened on or after date of first study medication dose and within 30 days following date of last study medication administration. Adverse Events were reported spontaneously by the participant and/or caregiver or observed by the investigator.
| Participants | All Participants (Lacosamide) |
|---|---|
| Number of Study Participants Withdrawn Due to TEAEs | 19 |
The number of study participants with appearance of new absence and/or myoclonic seizure types experienced during the Treatment Period but who did not experience in Combined Baseline Period or in seizure classification history, before taking LCM were reported. To determine appearance of new seizure type, the Combined Baseline Period was used. Thus, the participants who directly enrolled into EP0012, the Baseline absence, and/or myoclonic seizure data from SP0982's 4-week Prospective Baseline Period were combined with any reported Baseline absence, and myoclonic seizure information in the daily seizure diary from EP0012 (reported before first dose in EP0012) to recalculate the study participant's Baseline variables such as days with absence, and/or myoclonic seizures per 28 days.
| Participants | All Participants (Lacosamide) |
|---|---|
| Absence seizures | 3 |
| Myoclonic seizures | 5 |
The number of participants experiencing an increase of up to 25% in the number of days with absence seizures per 28 days during the Treatment Period compared to the Prospective Baseline Period (for those participants with absence seizure data reported in the 4-week Prospective Baseline Period in SP0982) were reported. This period started on the day of Visit 1 of SP0982 and ended the day before Visit 2 of SP0982. For the direct enrollers into EP0012, Prospective Baseline ended the day before Visit 1 (or prior to first dose) of EP0012.
| Participants | All Participants (Lacosamide) |
|---|---|
| Number of Study Participants With an Increase of up to 25% in Days With Absence Seizures Per 28 Days During the Treatment Period as Compared to the Prospective Baseline (of Study SP0982) | 5 |
The number of participants experiencing an increase of \>25% to 50% in the number of days with absence seizures per 28 days during the Treatment Period compared to the Prospective Baseline Period (for those participants with absence seizure data reported in the 4-week Prospective Baseline Period in SP0982) were reported. This period started on the day of Visit 1 of SP0982 and ended the day before Visit 2 of SP0982. For the direct enrollers into EP0012, Prospective Baseline ended the day before Visit 1 (or prior to first dose) of EP0012.
| Participants | All Participants (Lacosamide) |
|---|---|
| Number of Study Participants With an Increase of Greater Than (>)25% to 50% in Days With Absence Seizures Per 28 Days During the Treatment Period as Compared to the Prospective Baseline (of Study SP0982) | 1 |
The number of participants experiencing an increase of \>50% to 75% in the number of days with absence seizures per 28 days during the Treatment Period compared to the Prospective Baseline Period (for those participants with absence seizure data reported in the 4-week Prospective Baseline Period in SP0982) were reported. This period started on the day of Visit 1 of SP0982 and ended the day before Visit 2 of SP0982. For the direct enrollers into EP0012, Prospective Baseline ended the day before Visit 1 (or prior to first dose) of EP0012.
| Participants | All Participants (Lacosamide) |
|---|---|
| Number of Study Participants With an Increase of >50% to 75% in Days With Absence Seizures Per 28 Days During the Treatment Period as Compared to the Prospective Baseline (of Study SP0982) | 0 |
The number of participants experiencing an increase of \>75% in the number of days with absence seizures per 28 days during the Treatment Period compared to the Prospective Baseline Period (for those participants with absence seizure data reported in the 4-week Prospective Baseline Period in SP0982) were reported. This period started on the day of Visit 1 of SP0982 and ended the day before Visit 2 of SP0982. For the direct enrollers into EP0012, Prospective Baseline ended the day before Visit 1 (or prior to first dose) of EP0012.
| Participants | All Participants (Lacosamide) |
|---|---|
| Number of Study Participants With an Increase of >75% in Days With Absence Seizures Per 28 Days During the Treatment Period as Compared to the Prospective Baseline (of Study SP0982) | 0 |
The number of participants experiencing an increase of up to 25% in the number of days with myoclonic seizures per 28 days during the Treatment Period compared to the Prospective Baseline Period (for those participants with myoclonic seizure data reported in the 4-week Prospective Baseline Period in SP0982) were reported. This period started on the day of Visit 1 of SP0982 and ended the day before Visit 2 of SP0982. For the direct enrollers into EP0012, Prospective Baseline ended the day before Visit 1 (or prior to first dose) of EP0012.
| Participants | All Participants (Lacosamide) |
|---|---|
| Number of Study Participants With an Increase of up to 25% in Days With Myoclonic Seizures Per 28 Days During the Treatment Period as Compared to the Prospective Baseline (of Study SP0982) | 4 |
The number of participants experiencing an increase of \>25% to 50% in the number of days with myoclonic seizures per 28 days during the Treatment Period compared to the Prospective Baseline Period (for those participants with myoclonic seizure data reported in the 4-week Prospective Baseline Period in SP0982) were reported. This period started on the day of Visit 1 of SP0982 and ended the day before Visit 2 of SP0982. For the direct enrollers into EP0012, Prospective Baseline ended the day before Visit 1 (or prior to first dose) of EP0012.
| Participants | All Participants (Lacosamide) |
|---|---|
| Number of Study Participants With an Increase of >25% to 50% in Days With Myoclonic Seizures Per 28 Days During the Treatment Period as Compared to the Prospective Baseline (of Study SP0982) | 1 |
The number of participants experiencing an increase of \>50% to 75% in the number of days with myoclonic seizures per 28 days during the Treatment Period compared to the Prospective Baseline Period (for those participants with myoclonic seizure data reported in the 4-week Prospective Baseline Period in SP0982) were reported. This period started on the day of Visit 1 of SP0982 and ended the day before Visit 2 of SP0982. For the direct enrollers into EP0012, Prospective Baseline ended the day before Visit 1 (or prior to first dose) of EP0012.
| Participants | All Participants (Lacosamide) |
|---|---|
| Number of Study Participants With an Increase of >50% to 75% in Days With Myoclonic Seizures Per 28 Days During the Treatment Period as Compared to the Prospective Baseline (of Study SP0982) | 1 |
The number of participants experiencing an increase of \>75% in the number of days with myoclonic seizures per 28 days during the Treatment Period compared to the Prospective Baseline Period (for those participants with myoclonic seizure data reported in the 4-week Prospective Baseline Period in SP0982) were reported. This period started on the day of Visit 1 of SP0982 and ended the day before Visit 2 of SP0982. For the direct enrollers into EP0012, Prospective Baseline ended the day before Visit 1 (or prior to first dose) of EP0012.
| Participants | All Participants (Lacosamide) |
|---|---|
| Number of Study Participants With an Increase of >75% in Days With Myoclonic Seizures Per 28 Days During the Treatment Period as Compared to the Prospective Baseline (of Study SP0982) | 2 |
Seizure worsening was defined as a participant experiencing \>=50% increase in the number of days with absence seizures per 28 days from Prospective Baseline. Percentages for seizure worsening were based on those participants who have reported a history of or an occurrence of absence seizures in Prospective Baseline or the Treatment Period.
| percentage of participants | All Participants (Lacosamide) |
|---|---|
| Percentage of Study Participants With at Least 50% Worsening in Days With Absence Seizures | 0 |
Seizure worsening was defined as a participant experiencing \>=50% increase in the number of days with myoclonic seizures per 28 days from Prospective Baseline. Percentages for seizure worsening were based on those participants who have reported a history of or an occurrence of myoclonic seizures in Prospective Baseline or the Treatment Period.
| percentage of participants | All Participants (Lacosamide) |
|---|---|
| Percentage of Study Participants With at Least 50% Worsening in Days With Myoclonic Seizures | 3.2 |
TEMA values are defined in the Statistical Analysis Plan (SAP) as significant deviations from the expected range of age-appropriate values. TEMA laboratory results of Hematology parameter, Hemoglobin were those that were observed post-Baseline (BL) during the Treatment Period but not present at Baseline. For the age range, '2 years (y) to \<17 years', the abnormality criteria were '\<=95' grams/deciliter (g/dL) (Low) and '\>160' g/dL (High). For age range, '\>=17 years', the abnormality Criteria were '\<=85% of lower limit of normal (LLN)' value (Low) and '\>=115% of upper limit of normal (ULN)' value (High) of Hemoglobin in blood.
| percentage of participants | All Participants (Lacosamide) |
|---|---|
| Low: Week (Wk) 78 (2-<17 y) | 14.3 |
| Low: Wk 0 (>=17 y) | 3.7 |
| Low: Wk 2 (>=17 y) | 0.5 |
| Low: Wk 118 (>=17 y) | 0.8 |
| Low: Wk 166 (>=17 y) | 1.2 |
| Low: Wk 214 (>=17 y) | 2.5 |
| Low: Termination Visit (TV) (>=17 y) | 1.6 |
TEMA values are defined in the SAP as significant deviations from the expected range of age-appropriate values. TEMA laboratory results of Hematocrit were those that were observed post-BL during the Treatment Period but not present at BL. For the age range, '2 years to \<17 years', the abnormality criteria were '\<=29%' (Low) and '\>47%' (High) hematocrit values. For age range, '\>=17 years', the abnormality criteria were '\<=85% of LLN' (Low) and '\>=115% of ULN' (High) of Hematocrit values in blood.
| percentage of participants | All Participants (Lacosamide) |
|---|---|
| High: Wk 22 (2-<17 y) | 6.9 |
| High: Wk 46 (2-<17 y) | 3.7 |
| Low: Wk 46 (>=17 y) | 1.2 |
| Low: Wk 118 (>=17 y) | 1.6 |
| Low: Wk 166 (>=17 y) | 1.2 |
| Low: TV (>=17 y) | 0.8 |
TEMA values are defined in the SAP as significant deviations from the expected range of age-appropriate values. TEMA laboratory results of Platelet count were those that were observed post-BL during the Treatment Period but not present at BL. For the age range of '\>1 month', the abnormality criteria were '\<=100' 10\^9/L and '\>=600' 10\^9/L of Platelets count value.
| percentage of participants | All Participants (Lacosamide) |
|---|---|
| Percentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in Hematology Parameters (Platelets) | 0 |
TEMA values are defined in the SAP as significant deviations from the expected range of age-appropriate values. TEMA laboratory results of Erythrocytes parameter were those that were observed post-BL during the Treatment Period but not present at BL. For the age range, '\>=2years', the abnormality criteria were '\<3.5' 10\^12/L of Erythrocytes value in blood. Early Termination Visit (TV) was last visit in the study (up to approximately 5 years).
| percentage of participants | All Participants (Lacosamide) |
|---|---|
| Percentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in Hematology Parameters (Erythrocytes) | 1.7 |
TEMA values are defined in the SAP as significant deviations from the expected range of age-appropriate values. TEMA laboratory results of Leukocytes were those that were observed post-BL during the Treatment Period but not present at BL. For all age ranges, the abnormality criteria were '\<=3.0' 10\^9/L (Low) and '\>= 16.0' 10\^9/L (High) of Leukocytes values in blood.
| percentage of participants | All Participants (Lacosamide) |
|---|---|
| Percentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in Hematology Parameters (Leukocytes) | 0.5 |
TEMA values are defined in the SAP as significant deviations from the expected range of age-appropriate values. TEMA laboratory results of Basophils Absolute were those that were observed post-BL during the Treatment Period but not present at BL. For the age range, '\>1 month', the abnormality criteria were '\>=0.4' 10\^9/L of Basophils in blood.
| percentage of participants | All Participants (Lacosamide) |
|---|---|
| Percentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in Hematology Parameters (Basophils Absolute) | 0.4 |
TEMA values are defined in the SAP as significant deviations from the expected range of age-appropriate values. TEMA laboratory results of Eosinophils Absolute were those that were observed post-BL during the Treatment Period but not present at BL. For the age range, '\>1 month', the abnormality criteria were '\>=1.0' 10\^9/L of Eosinophils in the blood.
| percentage of participants | All Participants (Lacosamide) |
|---|---|
| >=1.0: Wk 2 (>1 month) | 0.9 |
| >=1.0: Wk 22 (>1 month) | 0.5 |
| >=1.0: TV (>1 month) | 1.5 |
TEMA values are defined in the SAP as significant deviations from the expected range of age-appropriate values. TEMA laboratory results of Lymphocytes Absolute were those that were observed post-Baseline (BL) during the Treatment Period but not present at Baseline. For the age range, '2 years - \<6 years', the abnormality criteria were '\<0.7' 10\^9/L (Low) and '\>6.9' 10\^9/L (High). For age range, '\>=6 years', the abnormality criteria were '\<0.6' 10\^9/L (Low) and '\>5.0' 10\^9/L (High) for Lymphocytes Absolute in the blood.
| percentage of participants | All Participants (Lacosamide) |
|---|---|
| High: Wk 2 (>=6 y) | 0.4 |
| High: Wk 78 (>=6 y) | 3.2 |
| High: Wk 118 (>=6 y) | 0.7 |
TEMA values are defined in the SAP as significant deviations from the expected range of age-appropriate values. TEMA laboratory results of Monocytes Absolute were those that are observed post-BL during the Treatment Period but not present at BL. For the age range, '\>1 month', the abnormality criteria was '\>=2.0' 10\^9/L of Monocytes in blood.
| percentage of participants | All Participants (Lacosamide) |
|---|---|
| Percentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in Hematology Parameters (Monocytes Absolute ) | 0 |
TEMA values are defined in the SAP as significant deviations from the expected range of age-appropriate values. TEMA laboratory results of Neutrophils Absolute were those that were observed post-BL during the Treatment Period but not present at BL. For the age range, '\>1 month', the abnormality criteria was '\<1.5' 10\^9/L of Neutrophils in blood.
| percentage of participants | All Participants (Lacosamide) |
|---|---|
| <1.5: Wk 2 (>1 m) | 0.9 |
| <1.5: Wk 22 (>1 m) | 0.5 |
| <1.5: Wk 46 (>1 m) | 0.5 |
| <1.5: Wk 62 (>1 m) | 0.5 |
| <1.5: Wk 94 (>1 m) | 0.6 |
| <1.5: Wk 214 (>1 m) | 2.4 |
TEMA values are defined in the SAP as significant deviations from the expected range of age-appropriate values. TEMA laboratory results of Calcium were those that were observed post- BL during the Treatment Period but not present at Baseline. For the age range, '1 year -\<17 years', the abnormality criteria were '\<=1.85' millimoles per litre (mmol/L) and '\>=2.95' mmol/L. For age range, '\>=17 years', the abnormality criteria was '\<=1.9 mmol/L' and '\>=2.75 mmol/L' of serum Calcium.
| percentage of participants | All Participants (Lacosamide) |
|---|---|
| Percentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in Serum Chemistry Parameters (Calcium) | 0 |
TEMA values are defined in the SAP as significant deviations from the expected range of age-appropriate values. TEMA laboratory results of Sodium were those that were observed post- BL during the Treatment Period but not present at Baseline. For the age range, '\>1 month', the abnormality criteria were '\<127' mmol/L (Low) and '\>151' mmol/L (High) of serum Sodium.
| percentage of participants | All Participants (Lacosamide) |
|---|---|
| Percentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in Serum Chemistry Parameters (Sodium) | 0 |
TEMA values are defined in the SAP as significant deviations from the expected range of age-appropriate values. TEMA laboratory results of Potassium were those that were observed post- BL during the Treatment Period but not present at Baseline. For the age range, '\>=1 year', the abnormality criteria were '\<= 3.0' mmol/L (Low) and '\>= 6.0' mmol/L (High) of serum Potassium.
| percentage of participants | All Participants (Lacosamide) |
|---|---|
| Percentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in Serum Chemistry Parameters (Potassium) | 0.4 |
TEMA values are defined in the SAP as significant deviations from the expected range of age-appropriate values. TEMA laboratory results of Chloride were those that were observed post- BL during the Treatment Period but not present at Baseline. For the age range, '\>1 month', the abnormality criteria were '\<=90' mmol/L (Low) and '\>=112' mmol/L (High) of serum Chloride.
| percentage of participants | All Participants (Lacosamide) |
|---|---|
| High: Wk 2 (>1 m) | 1.3 |
| High: Wk 22 (>1 m) | 2.3 |
| High: Wk 46 (>1 m) | 2.5 |
| High: Wk 62 (>1 m) | 1.5 |
| High: Wk 78 (>1 m) | 3.1 |
| High: Wk 94 (>1 m) | 1.2 |
| High: Wk 118 (>1 m) | 3.4 |
| High: Wk 214 (>1 m) | 2.3 |
| High: TV (>1 m) | 1.4 |
TEMA values are defined in the SAP as significant deviations from the expected range of age-appropriate values. TEMA laboratory results of Bicarbonate were those that were observed post- BL during the Treatment Period but not present at Baseline. For the age range, '\>1 month-\<17 years', the abnormality criteria were '\<15' mmol/L (Low) and '\>38' mmol/L (High). For age range, '\>=17 years', the abnormality criteria were '\<18' mmol/L (Low) and '\>38' mmol/L (High) of serum Bicarbonate.
| percentage of participants | All Participants (Lacosamide) |
|---|---|
| Low: Wk 2 (>=17 y) | 1.1 |
| Low: Wk 46 (>=17 y) | 1.2 |
| Low: Wk 62 (>=17 y) | 1.3 |
| Low: Wk 94 (>=17 y) | 0.7 |
TEMA values are defined in the SAP as significant deviations from the expected range of age-appropriate values. TEMA laboratory results of Creatinine were those that were observed post- BL during the Treatment Period but not present at Baseline. For the age range, '1-\<10 years', the abnormality criteria were '\>106.8' micromole per litre (umol/L), for '10-\<16 years', the abnormality criteria were '\>159.12' umol/L and for '\>=16 years', the abnormality criteria was '\>=176.8' umol/L for serum Creatinine.
| percentage of participants | All Participants (Lacosamide) |
|---|---|
| Percentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in Serum Chemistry Parameters (Creatinine) | 0 |
TEMA values are defined in the SAP as significant deviations from the expected range of age-appropriate values. TEMA laboratory results of Aspartate Aminotransferase (AST) were those that were observed post- BL during the Treatment Period but not present at Baseline. For all ages, the abnormality criteria were specified as '≥3.0 units per litre (U/L) x ULN' (High A), '≥5.0 U/L x ULN' (High B), and '≥10.0 U/L x ULN' (High C) of serum AST.
| percentage of participants | All Participants (Lacosamide) |
|---|---|
| High A: All ages (Early TV) | 1.7 |
| High A: All ages (TV) | 0.7 |
| High B: All ages (TV) | 0.7 |
| High C: All ages (TV) | 0.7 |
TEMA values are defined in the SAP as significant deviations from the expected range of age-appropriate values. TEMA laboratory results of Alanine Aminotransferase (ALT) were those that were observed post- BL during the Treatment Period but not present at Baseline. For all ages, the abnormality criteria were specified as '≥3.0 U/L x ULN' (High A), '≥5.0 U/L x ULN' (High B), and '≥10.0 U/L x ULN' (High C) of serum ALT.
| percentage of participants | All Participants (Lacosamide) |
|---|---|
| High A: All ages (Wk 2) | 0.4 |
| High A: All ages (Wk 46) | 0.5 |
| High A: All ages (Wk 62) | 0.5 |
| High A: All ages (Wk 118) | 0.7 |
| High A: All ages (TV) | 0.7 |
| High B: All ages (Wk 2) | 0.4 |
TEMA values are defined in the SAP as significant deviations from the expected range of age-appropriate values. TEMA laboratory results of Total Bilirubin were those that were observed post- BL during the Treatment Period but not present at Baseline. For the age range, '\>1 month', the abnormality criteria was '≥34.208' umol/L of serum Bilirubin.
| percentage of participants | All Participants (Lacosamide) |
|---|---|
| Percentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in Chemistry Parameters (Total Bilirubin) | 0.5 |
TEMA values are defined in the SAP as significant deviations from the expected range of age-appropriate values. TEMA laboratory results of Alkaline Phosphatase were those that were observed post- BL during the Treatment Period but not present at Baseline. For the age range, '4 years -\<10 years', the abnormality criteria was '\>=834 U/L', for '10 years -\<17 years', the abnormality criteria was '\>=1761 U/L' and for '\>=17 years', the abnormality criteria was '\>=3.0 U/L x ULN' of serum alkaline phosphatase.
| percentage of participants | All Participants (Lacosamide) |
|---|---|
| Percentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in Serum Chemistry Parameters (Alkaline Phosphatase) | 0 |
TEMA values are defined in the SAP as significant deviations from the expected range of age-appropriate values. TEMA laboratory results of Gamma Glutamyl Transferase (GGT) were those that were observed post- BL during the Treatment Period but not present at Baseline. For the age range, '1 year-\<13 years', the abnormality criteria was '\>=66' U/L (High A), for '13 years-\<17 years', the abnormality criteria was '\>=126' U/L (High B) and for '\>=17 years', the abnormality criteria was '\>=3.0 U/L x ULN' (High C) of serum GGT.
| percentage of participants | All Participants (Lacosamide) |
|---|---|
| High A: TV (1-<13 y) | 16.7 |
| High C: Wk 2 (>=17 y) | 1.0 |
| High C: Wk 22 (>=17 y) | 0.5 |
| High C: Wk 62 (>=17 y) | 1.8 |
| High C: Wk 78 (>=17 y) | 3.4 |
| High C: Wk 118 (>=17 y) | 0.8 |
| High C: Wk 166 (>=17 y) | 1.1 |
| High C:TV (>=17 y) | 0.8 |
TEMA values are defined in the SAP as significant deviations from the expected range of age-appropriate values. TEMA laboratory results of Glucose were those that were observed post- BL during the Treatment Period but not present at Baseline. For the age range, '\>1 month-\<17 years', the abnormality criteria were from '\<2.775' mmol/L (Low) and '\>=9.99' mmol/L (High). For age range, '\>=17 years', the abnormality criteria were '\<2.775' mmol/L (Low) and '\>=11.1' mmol/L (High) of serum Glucose.
| percentage of participants | All Participants (Lacosamide) |
|---|---|
| Low: Wk 2 (>=17 y) | 0.5 |
| Low: Wk 62 (>=17 y) | 0.6 |
| Low: Wk 94 (>=17 y) | 0.7 |
| Low: Wk 118 (>=17 y) | 0.8 |
| High: Wk 2 (>=17 y) | 1.0 |
| High: Wk 22 (>=17 y) | 1.1 |
| High: Wk 46 (>=17 y) | 1.2 |
| High: Wk 62 (>=17 y) | 1.8 |
| High: Wk 78 (>=17 y) | 3.4 |
| High: Wk 94 (>=17 y) | 0.7 |
| High: Wk 118 (>=17 y) | 0.8 |
| High: Early TV (>=17 y) | 1.9 |
TEMA values are defined in the SAP as significant deviations from the expected range of age-appropriate values. TEMA laboratory results of Albumin were those that were observed post- BL during the Treatment Period but not present at Baseline. For the age range, '\>=1 year to \<17 years', the abnormality criteria were '\<24' g/L and '\>84' g/L and for age range, '\>=17 years', the abnormality criteria was '\<26' g/L of serum albumin.
| percentage of participants | All Participants (Lacosamide) |
|---|---|
| Percentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in Serum Chemistry Parameters (Albumin) | 0 |
TEMA values are defined in the SAP as significant deviations from the expected range of age-appropriate values. TEMA laboratory results of Total Protein were those that were observed post- BL during the Treatment Period but not present at Baseline. For the age range, '1 year to \<17 years', the abnormality criteria were '\<43' g/L and '\>120' g/L. For age range, '\>=17 years', the abnormality criteria were '\<43' g/L and '\>130' g/L of serum protein.
| percentage of participants | All Participants (Lacosamide) |
|---|---|
| Percentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in Serum Chemistry Parameters (Total Protein) | 0 |
TEMA values are defined in the SAP as significant deviations from the expected range of age-appropriate values. TEMA laboratory results of Phosphate were those that are observed post- BL during the Treatment Period but not present at Baseline. For the age range, '1 year-\<17 years', the abnormality criteria were from '\<0.5814' mmol/L (Low) and '\>2.3902' mmol/L (High). For age range, '\>=17 years', the abnormality Criteria were '\<=0.646' mmol/L (Low) and '\>=1.938' mmol/L (High) of serum phosphate.
| percentage of participants | All Participants (Lacosamide) |
|---|---|
| Low: Wk 94 (>=17 y) | 0.7 |
| Low: Wk 118 (>=17 y) | 0.8 |
TEMA values are defined in the SAP as significant deviations from the expected range of age-appropriate values. TEMA ECG results of QT interval parameter were those that were observed post- BL during the Treatment Period but not present at Baseline. For the age range, '1 month (m)-\<12 years', the abnormality criteria were '\>=500 milliseconds (ms)' (Abnormal (Abn) A). For age range, '\>=12 years', the abnormality criteria were '\>=500 ms' (Abn B) or '\>=60 ms increase from Baseline' (Abn C). The abnormality in QT interval was observed at Week 0 as the participant was rolled over from SP0982 study and was constantly having abnormal ECG parameters while in SP0982 and EP0012.
| percentage of participants | All Participants (Lacosamide) |
|---|---|
| Abn C: Wk 0 (>=12 years) | 33.3 |
| Abn C: Wk 2 (>=12 years) | 0.5 |
| Abn C: Wk 14 (>=12 years) | 3.3 |
| Abn C: Wk 30 (>=12 years) | 0.8 |
| Abn B: Wk 46 (>=12 years) | 0.5 |
| Abn C: Wk 46 (>=12 years) | 2.7 |
| Abn C: Wk 62 (>=12 years) | 2.2 |
| Abn C: Wk 78 (>=12 years) | 1.6 |
| Abn C: Wk 94 (>=12 years) | 2.5 |
| Abn C: Wk 118 (>=12 years) | 13.0 |
| Abn C: Wk 142 (>=12 years) | 6.9 |
| Abn C: Wk 190 (>=12 years) | 3.2 |
| Abn C: Early TV (>=12 years) | 3.8 |
| Abn C: TV (>=12 years) | 2.3 |
TEMA values are defined in the SAP as significant deviations from the expected range of age-appropriate values. TEMA ECG results of QTc(F) interval were those that are observed post- BL during the Treatment Period but not present at Baseline. For the age range '3 years -\<12 years' and '\>=12 years- \<17 years', the abnormality criteria were from '\>440 ms' (Abn A) and '\>15% increase from Baseline' value (Abn B). For age range, '\>=17 years', the abnormality Criteria were '\>450 ms' (Abn C), '\>480 ms' (Abn D), '\>500 ms' (Abn E) or '\>=60 ms increase from Baseline' value (Abn F). The abnormality in QTc(F) interval was observed at Week 0 as the participant was rolled over from SP0982 study and was constantly having abnormal ECG parameters while in SP0982 and EP0012.
| percentage of participants | All Participants (Lacosamide) |
|---|---|
| Abn C: Wk 0 (>=17 y) | 33.3 |
| Abn D: Wk 0 (>=17 y) | 33.3 |
| Abn F: Wk 0 (>=17 y) | 33.3 |
| Abn C: Wk 2 (>=17 y) | 1.5 |
| Abn F: Wk 2 (>=17 y) | 1.0 |
| Abn A: Wk 14 (>=12 y-<17 y) | 5.6 |
| Abn C: Wk 14 (>=17 y) | 2.1 |
| Abn D: Wk 14 (>=17 y) | 1.0 |
| Abn E: Wk 14 (>=17 y) | 0.5 |
| Abn F: Wk 14 (>=17 y) | 3.7 |
| Abn F: Wk 30 (>=17 y) | 1.7 |
| Abn C: Wk 46 (>=17 y) | 5.2 |
| Abn D: Wk 46 (>=17 y) | 1.7 |
| Abn E: Wk 46 (>=17 y) | 1.2 |
| Abn F: Wk 46 (>=17 y) | 2.3 |
| Abn A: Wk 62 (>=12 y-<17 y) | 6.3 |
| Abn B: Wk 62 (>=12 y-<17 y) | 6.3 |
| Abn C: Wk 62 (>=17 y) | 2.4 |
| Abn D: Wk 62 (>=17 y) | 0.6 |
| Abn F: Wk 62 (>=17 y) | 1.8 |
| Abn F: Wk 78 (>=17 y) | 1.8 |
| Abn C: Wk 94 (>=17 y) | 2.7 |
| Abn D: Wk 94 (>=17 y) | 2.0 |
| Abn E: Wk 94 (>=17 y) | 2.0 |
| Abn F: Wk 94 (>=17 y) | 3.4 |
| Abn C: Wk 118 (>=17 y) | 9.5 |
| Abn F: Wk 118 (>=17 y) | 4.8 |
| Abn C: Wk 142 (>=17 y) | 2.1 |
| Abn F: Wk 142 (>=17 y) | 2.1 |
| Abn C: Early TV (>=17 y) | 6.1 |
| Abn D: Early TV (>=17 y) | 2.0 |
| Abn E: Early TV (>=17 y) | 2.0 |
| Abn F: Early TV (>=17 y) | 4.1 |
| Abn C: TV (>=17 y) | 2.8 |
| Abn F: TV (>=17 y) | 5.6 |
TEMA values are defined in the SAP as significant deviations from the expected range of age-appropriate values. TEMA ECG results of QTc(B) interval were those that are observed post- BL during the Treatment Period but not present at Baseline. For the age range '3 years -\<12 years' and '\>=12 years- \<17 years', the abnormality criteria were '\>450 ms' (Abn A) and '\>15% increase from Baseline' value (Abn B). For age range, '\>=17 years', the abnormality criteria were '\>450 ms' (Abn C), '\>480 ms' (Abn D), '\>500 ms' (Abn E) or '\>=60 ms increase from Baseline' value (Abn F). The abnormality in QTc(B) interval was observed at Week 0 as the participant was rolled over from SP0982 study and was constantly having abnormal ECG parameters while in SP0982 and EP0012.
| percentage of participants | All Participants (Lacosamide) |
|---|---|
| Abn C: Wk 0 (>=17 y) | 33.3 |
| Abn D: Wk 0 (>=17 y) | 33.3 |
| Abn E: Wk 0 (>=17 y) | 33.3 |
| Abn F: Wk 0 (>=17 y) | 33.3 |
| Abn C: Wk 2 (>=17 y) | 3.6 |
| Abn F: Wk 2 (>=17 y) | 2.0 |
| Abn A: Wk 14 (>=12 y-<17 y) | 5.6 |
| Abn C: Wk 14 (>=17 y) | 5.8 |
| Abn D: Wk 14 (>=17 y) | 1.6 |
| Abn E: Wk 14 (>=17 y) | 1.0 |
| Abn F: Wk 14 (>=17 y) | 3.7 |
| Abn C: Wk 30 (>=17 y) | 2.5 |
| Abn F: Wk 30 (>=17 y) | 1.7 |
| Abn C: Wk 46 (>=17 y) | 7.0 |
| Abn D: Wk 46 (>=17 y) | 2.9 |
| Abn E: Wk 46 (>=17 y) | 1.2 |
| Abn F: Wk 46 (>=17 y) | 3.5 |
| Abn A: Wk 62 (>=12 y-<17 y) | 6.3 |
| Abn B: Wk 62 (>=12 y-<17 y) | 6.3 |
| Abn C: Wk 62 (>=17 y) | 2.4 |
| Abn D: Wk 62 (>=17 y) | 0.6 |
| Abn E: Wk 62 (>=17 y) | 0.6 |
| Abn F: Wk 62 (>=17 y) | 3.5 |
| Abn C: Wk 78 (>=17 y) | 5.4 |
| Abn F: Wk 78 (>=17 y) | 1.8 |
| Abn C: Wk 94 (>=17 y) | 5.4 |
| Abn D: Wk 94 (>=17 y) | 2.0 |
| Abn E: Wk 94 (>=17 y) | 2.0 |
| Abn F: Wk 94 (>=17 y) | 3.4 |
| Abn A: Wk 118 (>=12 y-<17 y) | 50.0 |
| Abn C: Wk 118 (>=17 y) | 14.3 |
| Abn D: Wk 118 (>=17 y) | 4.8 |
| Abn E: Wk 118 (>=17 y) | 4.8 |
| Abn F: Wk 118 (>=17 y) | 9.5 |
| Abn A: Wk 142 (>=12 y-<17 y) | 9.1 |
| Abn C: Wk 142 (>=17 y) | 8.5 |
| Abn F: Wk 142 (>=17 y) | 4.3 |
| Abn F: Wk 166 (>=17 y) | 33.3 |
| Abn C: Wk 190 (>=17 y) | 7.7 |
| Abn F: Wk 190 (>=17 y) | 3.8 |
| Abn C: Early TV (>=17 y) | 6.1 |
| Abn D: Early TV (>=17 y) | 2.0 |
| Abn E: Early TV (>=17 y) | 2.0 |
| Abn F: Early TV (>=17 y) | 6.1 |
| Abn C: TV (>=17 y) | 2.8 |
| Abn D: TV (>=17 y) | 2.8 |
| Abn F: TV (>=17 y) | 5.6 |
TEMA values are defined in the SAP as significant deviations from the expected range of age-appropriate values. TEMA ECG results of PR interval were those that were observed post- BL during the Treatment Period but not present at Baseline. For the age range, '3 years -\<12 years', the abnormality criteria were '\>180 ms' (Abn A) and '\>25% increase from Baseline' value (Abn B). For the age range, '\>=12 years - \<17 years', the abnormality criteria were '\>200 ms' (Abn C) and '\>25% increase from Baseline' value (Abn D). For age range, '\>=17 years', the abnormality criteria were treatment-emergent values above '\>200 ms' (Abn E), '\>220 ms' (Abn F), or '\>250 ms' (Abn G).
| percentage of participants | All Participants (Lacosamide) |
|---|---|
| Abn B: Wk 2 (3 y-<12 y) | 6.3 |
| Abn D: Wk 2 (>=12 y-<17 y) | 5.0 |
| Abn E: Wk 2 (>=17 y) | 1.5 |
| Abn F: Wk 2 (>=17 y) | 0.5 |
| Abn E: Wk 14 (>=17 y) | 1.0 |
| Abn E: Wk 30 (>=17 y) | 1.7 |
| Abn F: Wk 30 (>=17 y) | 0.9 |
| Abn C: Wk 46 (>=12 y-<17 y) | 6.3 |
| Abn E: Wk 46 (>=17 y) | 1.2 |
| Abn B: Wk 62 (3 y-<12 y) | 20.0 |
| Abn C: Wk 62 (>=12 y-<17 y) | 6.3 |
| Abn E: Wk 62 (>=17 y) | 2.9 |
| Abn F: Wk 62 (>=17 y) | 0.6 |
| Abn E: Wk 78 (>=17 y) | 5.4 |
| Abn F: Wk 78 (>=17 y) | 1.8 |
| Abn G: Wk 78 (>=17 y) | 1.8 |
| Abn B: Wk 94 (3 y-<12 y) | 28.6 |
| Abn C: Wk 94 (>=12 y-<17 y) | 7.1 |
| Abn E: Wk 94 (>=17 y) | 2.7 |
| Abn F: Wk 94 (>=17 y) | 0.7 |
| Abn G: Wk 94 (>=17 y) | 0.7 |
| Abn D: Wk 118 (>=12 y-<17 y) | 50.0 |
| Abn E: Wk 142 (>=17 y) | 8.7 |
| Abn F: Wk 142 (>=17 y) | 2.2 |
| Abn E: Early TV (>=17 y) | 2.0 |
| Abn F: Early TV (>=17 y) | 2.0 |
TEMA values are defined in the SAP as significant deviations from the expected range of age-appropriate values. TEMA ECG results of QRS interval were those that were observed post- BL during the Treatment Period but not present at Baseline. For the age range, '3 years -\<12 years', the abnormality criteria were '\>100 ms' (Abn A) and '\>25% increase from Baseline' value (Abn B). For the age range, '\>=12 years - \<17 years', the abnormality criteria were '\>110 ms' (Abn C) and '\>25% increase from Baseline' (Abn D). For age range, '\>=17 years', the abnormality criteria were treatment-emergent values above '\>100 ms' (Abn E), '\>120 ms' (Abn F), or '\>140 ms' (Abn G).
| percentage of participants | All Participants (Lacosamide) |
|---|---|
| Abn E: Wk 2 (>=17 y) | 5.1 |
| Abn D: Wk 14 (>=12 y-<17 y) | 5.6 |
| Abn E: Wk 14 (>=17 y) | 9.9 |
| Abn F: Wk 14 (>=17 y) | 0.5 |
| Abn E: Wk 30 (>=17 y) | 7.6 |
| Abn A: Wk 46 (3 y-<12 y) | 8.3 |
| Abn D: Wk 46 (>=12 y-<17 y) | 6.3 |
| Abn E: Wk 46 (>=17 y) | 7.6 |
| Abn D: Wk 62 (>=12 y-<17 y) | 6.3 |
| Abn E: Wk 62 (>=17 y) | 10.6 |
| Abn F: Wk 62 (>=17 y) | 1.8 |
| Abn E: Wk 78 (>=17 y) | 8.9 |
| Abn F: Wk 78 (>=17 y) | 1.8 |
| Abn C: Wk 94 (>=12 y-<17 y) | 7.1 |
| Abn D: Wk 94 (>=12 y-<17 y) | 7.1 |
| Abn E: Wk 94 (>=17 y) | 6.1 |
| Abn F: Wk 94 (>=17 y) | 0.7 |
| Abn E: Wk 118 (>=17 y) | 14.3 |
| Abn E: Wk 142 (>=17 y) | 10.6 |
| Abn E: Early TV (>=17 y) | 10.2 |
| Abn E: TV (>=17 y) | 5.6 |
| Abn F: TV (>=17 y) | 5.6 |
TEMA values are defined in the SAP as significant deviations from the expected range of age-appropriate values. TEMA ECG results of Heart rate interval were those that were observed post- BL during the Treatment Period but not present at Baseline. For the age range, '3 years -\<12 years', the abnormality criteria were '\<60 beats per minute (bpm)' (Abn A) and '\>130 bpm' (Abn B). For the age range, '\>=12 years', the abnormality criteria were '\<50 bpm' (Abn C) and '\>120 bpm' (Abn D).
| percentage of participants | All Participants (Lacosamide) |
|---|---|
| Abn C: Wk 2 (>=12 y) | 1.4 |
| Abn C: Wk 14 (>=12 y) | 2.4 |
| Abn C: Wk 30 (>=12 y) | 1.5 |
| Abn C: Wk 46 (>=12 y) | 0.5 |
| Abn D: Wk 46 (>=12 y) | 0.5 |
| Abn C: Wk 62 (>=12 y) | 3.2 |
| Abn D: Wk 62 (>=12 y) | 0.5 |
| Abn C: Wk 78 (>=12 y) | 3.3 |
| Abn C: Wk 94 (>=12 y) | 1.2 |
| Abn C: Wk 118 (>=12 y) | 4.3 |
| Abn D: Wk 214 (>=12 y) | 100 |
| Abn D: TV (>=12 y) | 2.3 |
TEMA values are defined in the SAP as significant deviations from the expected range of age-appropriate values. TEMA vital signs results of Pulse rate were those that were observed post- BL during the Treatment Period but not present at Baseline. For the age range, '3 years -\<12 years', the abnormality criteria were '\<60 bpm' (Low) and '\>130 bpm' (High). For the age range, '12 years - \<17 years', the abnormality criteria were '\<=50 bpm' (Low) and '\>=120 bpm' (High). For the age range, '\>=17 years', the abnormality criteria were '\<=50 bpm and a decrease from Baseline of \>=15 bpm' (Low A), '\>=120 bpm and an increase from Baseline of \>=15 bpm' (High A), '\<60 bpm' (Low B) and '\>100 bpm' (High B). The Pulse rate was reported as per positions such as 'Supine 3 minute (Sup 3 min)', 'Standing 1 minute' (Std 1 min), and 'Standing 3 minute' (Std 3 min).
| percentage of participants | All Participants (Lacosamide) |
|---|---|
| Low B: Wk 2 (>=17 y)-Sup 3 min | 4.5 |
| High B: Wk 2 (>=17 y)- Sup 3 min | 0.5 |
| High: Wk 2 (>=12 y-<17 y)-Std 1 min | 5.0 |
| Low B: Wk 2 (>=17 y)-Std 1 min | 2.5 |
| High B: Wk 2 (>=17 y)-Std 1 min | 3.0 |
| Low B: Wk 2 (>=17 y)-Std 3 min | 1.5 |
| High B: Wk 2 (>=17 y)-Std 3 min | 2.6 |
| Low A: Wk 6 (>=17 y)-Sup 3 min | 0.5 |
| Low B: Wk 6 (>=17 y)-Sup 3 min | 4.6 |
| High B: Wk 6 (>=17 y)-Sup 3 min | 2.0 |
| High: Wk 6 (>=12 y-<17 y)- Std 1 min | 4.8 |
| Low B: Wk 6 (>=17 y)- Std 1 min | 1.5 |
| High B: Wk 6 (>=17 y)- Std 1 min | 3.1 |
| Low A: Wk 6 (>=17 y)- Std 3 min | 0.5 |
| Low B: Wk 6 (>=17 y)- Std 3 min | 1.0 |
| High B: Wk 6 (>=17 y)- Std 3 min | 2.6 |
| Low B: Wk 14 (>=17 y)- Sup 3 min | 4.1 |
| High B: Wk 14 (>=17 y)- Sup 3 min | 1.0 |
| High: Wk 14 (>=12 y-<17 y)- Std 1 min | 5.6 |
| Low B: Wk 14 (>=17 y)- Std 1 min | 3.1 |
| High B: Wk 14 (>=17 y)- Std 1 min | 2.6 |
| Low B: Wk 14 (>=17 y)- Std 3 min | 0.5 |
| High B: Wk 14 (>=17 y)- Std 3 min | 4.1 |
| Low B: Wk 22 (>=17 y)- Sup 3 min | 3.2 |
| High B: Wk 22 (>=17 y)- Sup 3 min | 0.5 |
| High A: Wk 22 (>=17 y)- Std 1 min | 0.5 |
| Low B: Wk 22 (>=17 y)- Std 1 min | 1.6 |
| High B: Wk 22 (>=17 y)- Std 1 min | 4.2 |
| Low B: Wk 22 (>=17 y)- Std 3 min | 2.1 |
| High B: Wk 22 (>=17 y)- Std 3 min | 3.7 |
| Low B: Wk 30 (>=17 y)- Sup 3 min | 1.7 |
| Low B: Wk 30 (>=17 y)- Std 1 min | 5.0 |
| High B: Wk 30 (>=17 y)- Std 1 min | 3.4 |
| Low B: Wk 30 (>=17 y)- Std 3 min | 2.5 |
| High B: Wk 30 (>=17 y)- Std 3 min | 1.7 |
| Low B: Wk 38 (>=17 y)- Sup 3 min | 3.7 |
| Low B: Wk 38 (>=17 y)- Std 1 min | 2.8 |
| High B: Wk 38 (>=17 y)- Std 1 min | 5.6 |
| Low B: Wk 38 (>=17 y)- Std 3 min | 0.9 |
| High B: Wk 38 (>=17 y)- Std 3 min | 2.8 |
| Low B: Wk 46 (>=17 y)- Sup 3 min | 5.7 |
| High B: Wk 46 (>=17 y)- Sup 3 min | 1.7 |
| Low A: Wk 46 (>=17 y)- Std 1 min | 0.6 |
| High A: Wk 46 (>=17 y)- Std 1 min | 1.1 |
| Low B: Wk 46 (>=17 y)- Std 1 min | 4.0 |
| High B: Wk 46 (>=17 y)- Std 1 min | 5.2 |
| Low B: Wk 46 (>=17 y)- Std 3 min | 2.9 |
| High B: Wk 46 (>=17 y)- Std 3 min | 4.6 |
| Low B: Wk 62 (>=17 y)- Sup 3 min | 5.2 |
| High B: Wk 62 (>=17 y)- Sup 3 min | 2.3 |
| Low: Wk 62 (>=12 y-<17 y)- Std 1 min | 6.3 |
| High A: Wk 62 (>=17 y)- Std 1 min | 0.6 |
| Low B: Wk 62 (>=17 y)- Std 1 min | 4.6 |
| High B: Wk 62 (>=17 y)- Std 1 min | 4.0 |
| High A: Wk 62 (>=17 y)- Std 3 min | 0.6 |
| Low B: Wk 62 (>=17 y)- Std 3 min | 2.3 |
| High B: Wk 62 (>=17 y)- Std 3 min | 2.9 |
| Low B: Wk 78 (>=17 y)- Sup 3 min | 6.7 |
| High B: Wk 78 (>=17 y)- Sup 3 min | 1.7 |
| Low B: Wk 78 (>=17 y)- Std 1 min | 6.7 |
| High B: Wk 78 (>=17 y)- Std 1 min | 6.7 |
| Low B: Wk 78 (>=17 y)- Std 3 min | 6.7 |
| High B: Wk 78 (>=17 y)- Std 3 min | 5.0 |
| Low B: Wk 94 (>=17 y)- Sup 3 min | 6.1 |
| High B: Wk 94 (>=17 y)- Sup 3 min | 0.7 |
| Low B: Wk 94 (>=17 y)- Std 1 min | 2.7 |
| High B: Wk 94 (>=17 y)- Std 1 min | 4.1 |
| Low B: Wk 94 (>=17 y)- Std 3 min | 1.4 |
| High B: Wk 94 (>=17 y)- Std 3 min | 2.7 |
| Low B: Wk 118 (>=17 y)- Sup 3 min | 2.2 |
| High B: Wk 118 (>=17 y)- Sup 3 min | 2.2 |
| Low B: Wk 118 (>=17 y)- Std 1 min | 2.2 |
| High B: Wk 118 (>=17 y)- Std 1 min | 3.3 |
| Low B: Wk 118 (>=17 y)- Std 3 min | 2.2 |
| High B: Wk 118 (>=17 y)- Std 3 min | 4.4 |
| High A: Wk 142 (>=17 y)- Sup 3 min | 1.6 |
| Low B: Wk 142 (>=17 y)- Sup 3 min | 6.3 |
| High B: Wk 142 (>=17 y)- Sup 3 min | 4.8 |
| High A: Wk 142 (>=17 y)- Std 1 min | 3.2 |
| High B: Wk 142 (>=17 y)- Std 1 min | 7.9 |
| High A: Wk 142 (>=17 y)- Std 3 min | 1.6 |
| Low B: Wk 142 (>=17 y)- Std 3 min | 3.2 |
| High B: Wk 142 (>=17 y)- Std 3 min | 7.9 |
| Low B: Wk 166 (>=17 y)- Sup 3 min | 3.8 |
| High B: Wk 166 (>=17 y)- Sup 3 min | 1.9 |
| Low B: Wk 166 (>=17 y)- Std 1 min | 2.0 |
| High B: Wk 166 (>=17 y)- Std 1 min | 5.9 |
| High B: Wk 166 (>=17 y)- Std 3 min | 5.9 |
| Low B: Wk 190 (>=17 y)- Sup 3 min | 2.9 |
| High B: Wk 190 (>=17 y)- Sup 3 min | 8.8 |
| High B: Wk 190 (>=17 y)- Std 1 min | 11.8 |
| High B: Wk 190 (>=17 y)- Std 3 min | 17.6 |
| High B: Wk 214 (>=17 y)- Sup 3 min | 5.9 |
| High B: Wk 214 (>=17 y)- Std 1 min | 5.9 |
| High B: Wk 214 (>=17 y)- Std 3 min | 5.9 |
| Low B: Early TV (>=17 y)- Sup 3 min | 3.6 |
| High B: Early TV (>=17 y)- Sup 3 min | 1.8 |
| High: Early TV (>=12 y-<17 y)- Std 1 min | 33.3 |
| Low B: Early TV (>=17 y)- Std 1 min | 3.6 |
| High B: Early TV (>=17 y)- Std 1 min | 5.5 |
| Low A: TV (>=17 years)- Sup 3 min | 2.0 |
| Low B: TV (>=17 years)- Sup 3 min | 4.0 |
| High B: TV (>=17 years)- Sup 3 min | 2.0 |
| Low B: TV (>=17 years)- Std 1 min | 2.0 |
| High B: TV (>=17 years)- Std 1 min | 4.0 |
| Low B: TV (>=17 years)- Std 3 min | 2.0 |
| High B: TV (>=17 years)- Std 3 min | 2.0 |
TEMA values of Systolic Blood Pressure (BP) results were those that were observed post- BL during the Treatment Period but not present at Baseline. For the age range, '3 years -\<12 years', the abnormality criteria were '\<80 millimeters of mercury (mmHg)' (Low) and '\>140 mmHg' (High). For the age range, '\>=12 years - \<17 years', the abnormality criteria were '\<90 mmHg' (Low) and '\>160 mmHg' (High). For the age range, '\>=17 years', the abnormality criteria were '\<=90 mmHg and decrease from Baseline of \>=20 mmHg' (Low A), '\>=180 mmHg and increase from Baseline of \>=20' mmHg (High A), '\<90 mmHg' (Low B), '\>140 mmHg (High B), and '\>160 mmHg' (High C). Systolic BP were reported as per positions such as 'Sup 3 min', 'Std 1 min, and 'Std 3 min'.
| percentage of participants | All Participants (Lacosamide) |
|---|---|
| High B: Wk 2 (>=17 y)- Sup 3 min | 3.5 |
| Low B: Wk 2 (>=17 y)- Std 1 min | 1.0 |
| High B: Wk 2 (>=17 y)- Std 1 min | 2.5 |
| High B: Wk 2 (>=17 y)- Std 3 min | 3.6 |
| High B: Wk 6 (>=17 y)- Sup 3 min | 3.1 |
| High B: Wk 6 (>=17 y)- Std 1 min | 2.0 |
| Low B: Wk 6 (>=17 y)- Std 3 min | 0.5 |
| High B: Wk 6 (>=17 y)- Std 3 min | 3.6 |
| Low B: Wk 14 (>=17 y)- Sup 3 min | 0.5 |
| High B: Wk 14 (>=17 y)- Sup 3 min | 3.1 |
| High B: Wk 14 (>=17 y)- Std 1 min | 3.6 |
| High B: Wk 14 (>=17 y)- Std 3 min | 3.6 |
| High B: Wk 22 (>=17 y)- Sup 3 min | 4.2 |
| High B: Wk 22 (>=17 y)- Std 1 min | 4.2 |
| High B: Wk 22 (>=17 y)- Std 3 min | 3.7 |
| Low B: Wk 30 (>=17 y)- Sup 3 min | 0.8 |
| High B: Wk 30 (>=17 y)- Sup 3 min | 5.9 |
| High B: Wk 30 (>=17 y)- Std 1 min | 2.5 |
| High B: Wk 30 (>=17 y)- Std 3 min | 5.0 |
| Low B: Wk 38 (>=17 y)- Sup 3 min | 0.9 |
| High B: Wk 38 (>=17 y)- Sup 3 min | 2.8 |
| Low B: Wk 38 (>=17 y)- Std 1 min | 0.9 |
| High B: Wk 38 (>=17 y)- Std 1 min | 2.8 |
| High B: Wk 38 (>=17 y)- Std 3 min | 3.7 |
| Low: Wk 46 (>=12 y-<17 y)- Sup 3 min | 6.3 |
| High B: Wk 46 (>=17 y)- Sup 3 min | 2.9 |
| Low: Wk 46 (>=12 y-<17 y)- Std 1 min | 6.3 |
| High B: Wk 46 (>=17 y)- Std 1 min | 2.3 |
| Low: Wk 46 (>=12 y-<17 y)- Std 3 min | 6.3 |
| High B: Wk 46 (>=17 y)- Std 3 min | 3.4 |
| High C: Wk 46 (>=17 y)- Std 3 min | 0.6 |
| Low B: Wk 62 (>=17 y)- Sup 3 min | 0.6 |
| High B: Wk 62 (>=17 y)- Sup 3 min | 3.5 |
| Low: Wk 62 (>=12 y-<17 y)- Std 1 min | 6.3 |
| Low A: Wk 62 (>=17 y)- Std 1 min | 0.6 |
| Low B: Wk 62 (>=17 y)- Std 1 min | 0.6 |
| High B: Wk 62 (>=17 y)- Std 1 min | 2.3 |
| Low A: Wk 62 (>=17 y)- Std 3 min | 0.6 |
| Low B: Wk 62 (>=17 y)- Std 3 min | 1.7 |
| High B: Wk 62 (>=17 y)- Std 3 min | 1.2 |
| Low A: Wk 78 (>=17 y)- Sup 3 min | 1.7 |
| High B: Wk 78 (>=17 y)- Sup 3 min | 1.7 |
| High B: Wk 78 (>=17 y)- Std 1 min | 1.7 |
| High B: Wk 78 (>=17 y)- Std 3 min | 1.7 |
| High B: Wk 94 (>=17 y)- Sup 3 min | 4.1 |
| High B: Wk 94 (>=17 y)- Std 1 min | 4.1 |
| High B: Wk 94 (>=17 y)- Std 3 min | 4.1 |
| High B: Wk 118 (>=17 y)- Sup 3 min | 5.4 |
| High C: Wk 118 (>=17 y)- Sup 3 min | 1.1 |
| High B: Wk 118 (>=17 y)- Std 1 min | 5.5 |
| High C: Wk 118 (>=17 y)- Std 1 min | 1.1 |
| High B: Wk 118 (>=17 y)- Std 3 min | 6.6 |
| High C: Wk 118 (>=17 y)- Std 3 min | 1.1 |
| High B: Wk 142 (>=17 y)- Sup 3 min | 6.3 |
| High B: Wk 142 (>=17 y)- Std 1 min | 6.3 |
| High B: Wk 142 (>=17 y)- Std 3 min | 6.3 |
| High B: Wk 166 (>=17 y)- Sup 3 min | 3.8 |
| High B: Wk 166 (>=17 y)- Std 1 min | 7.8 |
| High B: Wk 166 (>=17 y)- Std 3 min | 7.8 |
| High B: Wk 190 (>=17 y)- Sup 3 min | 2.9 |
| High B: Wk 214 (>=17 y)- Std 1 min | 5.9 |
| High C: Wk 214 (>=17 y)- Std 1 min | 5.9 |
| High B: Wk 214 (>=17 y)- Std 3 min | 5.9 |
| High B: Wk 262 (>=17 y)- Std 3 min | 100 |
| High B: Early TV (>=17 y)- Sup 3 min | 1.8 |
| High B: Early TV (>=17 y)- Std 1 min | 1.8 |
| High B: TV (>=17 y)- Std 1 min | 4.0 |
| High B: TV (>=17 y)- Std 3 min | 2.0 |
TEMA values of Diastolic BP results were those that are observed post- BL during the Treatment Period but not present at Baseline. For the age range, '3 years -\<12 years', the abnormality criteria were '\<50 mmHg' (Low) and '\>80 mmHg' (High), '\>=12 years - \<17 years', the abnormality criteria were '\<=50 mmHg' (Low) and '\>=105 mmHg' (High), and '\>=17 years', the abnormality criteria were '\<=50 mmHg and decrease from Baseline of \>=15 mmHg' (Low A), '\>=105 mmHg and increase from Baseline of \>=15' mmHg (High A), '\<50 mmHg' (Low B), '\>90 mmHg' (High B), and '\>100 mmHg' (High C). Diastolic BP were reported as per positions such as 'Sup 3 min', 'Std 1 min, and 'Std 3 min'.
| percentage of participants | All Participants (Lacosamide) |
|---|---|
| Low: Wk 2 (3 y-<12 y)- Sup 3 min | 6.3 |
| Low B: Wk 2 (>=17 y)- Sup 3 min | 0.5 |
| High B: Wk 2 (>=17 y)- Sup 3 min | 2.5 |
| Low: Wk 2 (3 y-<12 y)- Std 1 min | 6.3 |
| High: Wk 2 (3 y-<12 y)- Std 1 min | 6.3 |
| High B: Wk 2 (>=17 y)- Std 1 min | 5.1 |
| High C: Wk 2 (>=17 y)- Std 1 min | 0.5 |
| Low: Wk 2 (3 y-<12 y)- Std 3 min | 6.3 |
| High: Wk 2 (3 y-<12 y)- Std 3 min | 12.5 |
| High B: Wk 2 (>=17 y)- Std 3 min | 6.1 |
| High C: Wk 2 (>=17 y)- Std 3 min | 0.5 |
| Low A: Wk 6 (>=17 y)- Sup 3 min | 0.5 |
| High B: Wk 6 (>=17 y)- Sup 3 min | 4.6 |
| High C: Wk 6 (>=17 y)- Sup 3 min | 0.5 |
| Low A: Wk 6 (>=17 y)- Std 1 min | 0.5 |
| High A: Wk 6 (>=17 y)- Std 1 min | 0.5 |
| High B: Wk 6 (>=17 y)- Std 1 min | 4.1 |
| High C: Wk 6 (>=17 y)- Std 1 min | 0.5 |
| High: Wk 6 (3 y-<12 y)- Std 3 min | 7.1 |
| Low A: Wk 6 (>=17 y)- Std 3 min | 0.5 |
| Low B: Wk 6 (>=17 y)- Std 3 min | 0.5 |
| High B: Wk 6 (>=17 y)- Std 3 min | 6.6 |
| High C: Wk 6 (>=17 y)- Std 3 min | 0.5 |
| High: Wk 14 (3 y-<12 y)- Sup 3 min | 7.7 |
| High B: Wk 14 (>=17 y)- Sup 3 min | 2.0 |
| High C: Wk 14 (>=17 y)- Sup 3 min | 0.5 |
| High A: Wk 14 (>=17 y)- Std 1 min | 0.5 |
| High B: Wk 14 (>=17 y)- Std 1 min | 3.1 |
| High C: Wk 14 (>=17 y)- Std 1 min | 1.0 |
| High: Wk 14 (3 y-<12 y)- Std 3 min | 8.3 |
| High B: Wk 14 (>=17 y)- Std 3 min | 4.6 |
| High C: Wk 14 (>=17 y)- Std 3 min | 0.5 |
| High: Wk 22 (3 y-<12 y)- Sup 3 min | 15.4 |
| Low: Wk 22 (>=12 y-<17 y)- Sup 3 min | 6.3 |
| High B: Wk 22 (>=17 y)- Sup 3 min | 1.6 |
| High C: Wk 22 (>=17 y)- Sup 3 min | 0.5 |
| High: Wk 22 (3 y-<12 y)- Std 1 min | 15.4 |
| Low A: Wk 22 (>=17 y)- Std 1 min | 1.1 |
| Low B: Wk 22 (>=17 y)- Std 1 min | 0.5 |
| High B: Wk 22 (>=17 y)- Std 1 min | 7.9 |
| High C: Wk 22 (>=17 y)- Std 1 min | 0.5 |
| High: Wk 22 (3 y-<12 y)- Std 3 min | 7.7 |
| Low A: Wk 22 (>=17 y)- Std 3 min | 0.5 |
| High B: Wk 22 (>=17 y)- Std 3 min | 6.3 |
| High C: Wk 22 (>=17 y)- Std 3 min | 1.1 |
| High B: Wk 30 (>=17 y)- Sup 3 min | 3.4 |
| High C: Wk 30 (>=17 y)- Sup 3 min | 0.8 |
| High: Wk 30 (3 y-<12 y)- Std 1 min | 14.3 |
| High A: Wk 30 (>=17 y)- Std 1 min | 0.8 |
| High B: Wk 30 (>=17 y)- Std 1 min | 5.9 |
| High C: Wk 30 (>=17 y)- Std 1 min | 0.8 |
| High B: Wk 30 (>=17 y)- Std 3 min | 4.2 |
| High B: Wk 38 (>=17 y)- Sup 3 min | 2.8 |
| High: Wk 38 (3 y-<12 y)- Std 1 min | 20.0 |
| High B: Wk 38 (>=17 y)- Std 1 min | 5.6 |
| High C: Wk 38 (>=17 y)- Std 1 min | 0.9 |
| High B: Wk 38 (>=17 y)- Std 3 min | 9.3 |
| Low A: Wk 46 (>=17 y)- Sup 3 min | 0.6 |
| High B: Wk 46 (>=17 y)- Sup 3 min | 4.0 |
| Low: Wk 46 (>=12 y-<17 y)- Std 1 min | 6.3 |
| High B: Wk 46 (>=17 y)- Std 1 min | 8.0 |
| High C: Wk 46 (>=17 y)- Std 1 min | 0.6 |
| High B: Wk 46 (>=17 y)- Std 3 min | 9.8 |
| High C: Wk 46 (>=17 y)- Std 3 min | 1.1 |
| High A: Wk 62 (>=17 y)- Sup 3 min | 0.6 |
| High B: Wk 62 (>=17 y)- Sup 3 min | 5.2 |
| High C: Wk 62 (>=17 y)- Sup 3 min | 1.2 |
| High: Wk 62 (3 y-<12 y)- Std 1 min | 20.0 |
| Low: Wk 62 (>=12 y-<17 y)- Std 1 min | 6.3 |
| High A: Wk 62 (>=17 y)- Std 1 min | 0.6 |
| High B: Wk 62 (>=17 y)- Std 1 min | 5.8 |
| High C: Wk 62 (>=17 y)- Std 1 min | 1.2 |
| Low B: Wk 62 (>=17 y)- Std 3 min | 0.6 |
| High B: Wk 62 (>=17 y)- Std 3 min | 5.8 |
| High C: Wk 62 (>=17 y)- Std 3 min | 0.6 |
| Low: Wk 78 (>=12 y-<17 y)- Sup 3 min | 16.7 |
| High B: Wk 78 (>=17 y)- Sup 3 min | 1.7 |
| High B: Wk 78 (>=17 y)- Std 1 min | 3.3 |
| High B: Wk 78 (>=17 y)- Std 3 min | 3.3 |
| High C: Wk 78 (>=17 y)- Std 3 min | 1.7 |
| High B: Wk 94 (>=17 y)- Sup 3 min | 1.4 |
| High B: Wk 94 (>=17 y)- Std 1 min | 4.1 |
| High: Wk 94 (3 y-<12 y)- Std 3 min | 14.3 |
| High A: Wk 94 (>=17 y)- Std 3 min | 0.7 |
| High B: Wk 94 (>=17 y)- Std 3 min | 4.7 |
| High C: Wk 94 (>=17 y)- Std 3 min | 0.7 |
| Low A: Wk 118 (>=17 y)- Sup 3 min | 1.1 |
| High A: Wk 118 (>=17 y)- Sup 3 min | 1.1 |
| Low B: Wk 118 (>=17 y)- Sup 3 min | 1.1 |
| High B: Wk 118 (>=17 y)- Sup 3 min | 2.2 |
| High C: Wk 118 (>=17 y)- Sup 3 min | 1.1 |
| Low A: Wk 118 (>=17 y)- Std 1 min | 1.1 |
| Low B: Wk 118 (>=17 y)- Std 1 min | 1.1 |
| High B: Wk 118 (>=17 y)- Std 1 min | 4.4 |
| High B: Wk 118 (>=17 y)- Std 3 min | 7.7 |
| High B: Wk 142 (>=17 y)- Sup 3 min | 6.3 |
| High B: Wk 142 (>=17 y)- Std 1 min | 7.9 |
| High B: Wk 142 (>=17 y)- Std 3 min | 7.9 |
| High B: Wk 166 (>=17 y)- Sup 3 min | 3.8 |
| High B: Wk 166 (>=17 y)- Std 1 min | 5.9 |
| High A: Wk 166 (>=17 y)- Std 3 min | 2.0 |
| High B: Wk 166 (>=17 y)- Std 3 min | 11.8 |
| High C: Wk 166 (>=17 y)- Std 3 min | 2.0 |
| High B: Wk 190 (>=17 y)- Std 3 min | 2.9 |
| High B: Wk 214 (>=17 y)- Sup 3 min | 5.9 |
| High A: Wk 214 (>=17 y)- Std 1 min | 5.9 |
| High B: Wk 214 (>=17 y)- Std 1 min | 5.9 |
| High C: Wk 214 (>=17 y)- Std 1 min | 5.9 |
| High A: Wk 214 (>=17 y)- Std 3 min | 5.9 |
| High B: Wk 214 (>=17 y)- Std 3 min | 5.9 |
| High C: Wk 214 (>=17 y)- Std 3 min | 5.9 |
| High B: Early TV (>=17 y)- Sup 3 min | 3.6 |
| High C: Early TV (>=17 y)- Sup 3 min | 1.8 |
| High B: Early TV (>=17 y)- Std 1 min | 9.1 |
| High C: Early TV (>=17 y)- Std 1 min | 1.8 |
| High A: Early TV (>=17 y)- Std 3 min | 1.8 |
| High B: Early TV (>=17 y)- Std 3 min | 10.9 |
| High C: Early TV (>=17 y)- Std 3 min | 3.6 |
| High: TV (3 y-<12 y)- Sup 3 min | 16.7 |
| High B: TV (>=17 y)- Sup 3 min | 4.0 |
| High B: TV (>=17 y)- Std 1 min | 2.0 |
| High B: TV (>=17 y)- Std 3 min | 4.0 |
| High C: TV (>=17 y)- Std 3 min | 2.0 |
TEMA values are defined in the SAP as significant deviations from the expected range of age-appropriate values. TEMA vital signs parameter results were those that are observed post- BL during the Treatment Period but not present at Baseline. For the age range, '1 month - \<17 years', the abnormality criteria were '\<3% of normal body weight' in Kilograms (kg) or '\>97% of normal body weight' in kgs. Here, '\<3% of normal' is presented as 'Low' and '\>97% of normal' is presented as 'High'. For the age range '\>=17 years', the abnormality criteria were 'Increase/decrease of \>=10%' body weight in kgs (presented as Inc/Dec A) or 'Increase/decrease of \>=7%' body weight in kgs (presented as Inc/Dec B).
| percentage of participants | All Participants (Lacosamide) |
|---|---|
| High- Wk 14 (1 m - <17 y) | 9.7 |
| Inc/Dec A- Wk 14 (>=17 y) | 5.6 |
| Inc/Dec B- Wk 14 (>=17 y) | 16.4 |
| High- Wk 30 (1 m - <17 y) | 10.5 |
| Inc/Dec A- Wk 30 (>=17 y) | 5.9 |
| Inc/Dec B- Wk 30 (>=17 y) | 19.3 |
| High- Wk 46 (1 m - <17 y) | 7.1 |
| Inc/Dec A- Wk 46 (>=17 y) | 12.4 |
| Inc/Dec B- Wk 46 (>=17 y) | 22.6 |
| High- Wk 62 (1 m - <17 y) | 7.7 |
| Inc/Dec A- Wk 62 (>=17 y) | 14.9 |
| Inc/Dec B- Wk 62 (>=17 y) | 21.8 |
| Inc/Dec A- Wk 78 (>=17 y) | 19.0 |
| Inc/Dec B- Wk 78 (>=17 y) | 30.2 |
| High- Wk 94 (1 m - <17 y) | 13.0 |
| Inc/Dec A- Wk 94 (>=17 y) | 16.4 |
| Inc/Dec B- Wk 94 (>=17 y) | 30.9 |
| Low- Wk 118 (1 m - <17 y) | 5.3 |
| High- Wk 118 (1 m - <17 y) | 10.5 |
| Inc/Dec A- Wk 118 (>=17 y) | 21.6 |
| Inc/Dec B- Wk 118 (>=17 y) | 33.0 |
| Low- Wk 142 (1 m - <17 y) | 7.7 |
| High- Wk 142 (1 m - <17 y) | 7.7 |
| Inc/Dec A- Wk 142 (>=17 y) | 19.5 |
| Inc/Dec B- Wk 142 (>=17 y) | 32.5 |
| High- Wk 166 (1 m - <17 y) | 10.0 |
| Inc/Dec A- Wk 166 (>=17 y) | 25.0 |
| Inc/Dec B- Wk 166 (>=17 y) | 45.0 |
| Low- Wk 190 (1 m - <17 y) | 16.7 |
| Inc/Dec A- Wk 190 (>=17 y) | 26.1 |
| Inc/Dec B- Wk 190 (>=17 y) | 50.0 |
| Low- Wk 214 (1 m - <17 y) | 50.0 |
| Inc/Dec A- Wk 214 (>=17 y) | 31.8 |
| Inc/Dec B- Wk 214 (>=17 y) | 54.5 |
| Inc/Dec A- Wk 238 (>=17 y) | 16.7 |
| Inc/Dec B- Wk 238 (>=17 y) | 50.0 |
| Inc/Dec A- Wk 262 (>=17 y) | 33.3 |
| Inc/Dec B- Wk 262 (>=17 y) | 33.3 |
| Inc/Dec A- Early TV (>=17 y) | 26.3 |
| Inc/Dec B- Early TV (>=17 y) | 33.3 |
| High- TV (1 m - <17 y) | 21.4 |
| Inc/Dec A- TV (>=17 y) | 34.5 |
| Inc/Dec B- TV (>=17 y) | 52.7 |
The 28-day PGTCS frequency during the relative period was subtracted from the 28-day Combined Baseline PGTCS frequency and the result was divided by 28-day Combined Baseline PGTCS frequency and the result was then multiplied by 100 to get percent change in PGTCS frequency per 28 days from Combined Baseline Period (CB) to the appropriate analysis Period. The CB was defined as the combined 12-week Historical Baseline and 4-week Prospective Baseline periods immediately prior to randomization in the study SP0982 or prior to Visit 1 (first dose) if direct enrollers in EP0012.
| percent change | All Participants (Lacosamide) |
|---|---|
| Percent Change in Primary Generalized Tonic-clonic Seizure (PGTCS) Frequency Per 28 Days From Combined Baseline | -88.58 (-100.0 to 465.4) |
Collected over From Visit 1 (Week 0) to End of Treatment Period (up to approximately 5 years). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| All Participants (Lacosamide) | 4/239 (1.7%) | 54/239 (22.6%) | 176/239 (73.6%) |
| Event | All Participants (Lacosamide) |
|---|---|
| Grand mal convulsionNervous system disorders | 16/239 |
| Status epilepticusNervous system disorders | 4/239 |
| VomitingGastrointestinal disorders | 2/239 |
| Head injuryInjury, poisoning and procedural complications | 2/239 |
| Facial bones fractureInjury, poisoning and procedural complications | 2/239 |
| Subdural haematomaInjury, poisoning and procedural complications | 2/239 |
| Myoclonic epilepsyNervous system disorders | 2/239 |
| Suicide attemptPsychiatric disorders | 2/239 |
| Pneumonia aspirationRespiratory, thoracic and mediastinal disorders | 2/239 |
| Cardiac failureCardiac disorders | 1/239 |
| Event | All Participants (Lacosamide) |
|---|---|
| HeadacheNervous system disorders | 56/239 |
| DizzinessNervous system disorders | 53/239 |
| NasopharyngitisInfections and infestations | 52/239 |
| SomnolenceNervous system disorders | 40/239 |
| ContusionInjury, poisoning and procedural complications | 24/239 |
| NauseaGastrointestinal disorders | 23/239 |
| VertigoEar and labyrinth disorders | 19/239 |
| DiarrhoeaGastrointestinal disorders | 18/239 |
| InfluenzaInfections and infestations | 18/239 |
| Upper respiratory tract infectionInfections and infestations | 17/239 |
Baseline Characteristics refer to the Safety Set which consisted of all study participants who received at least 1 dose of IMP during this study.
| Age, Continuous(years) | All Participants (Lacosamide) |
|---|---|
| Mean | 27.9 ± 12.6 |
| Age, Customized(Participants) | All Participants (Lacosamide) |
|---|---|
| ≥4-<12 years | 16 |
| 12-<18 years | 28 |
| 18-<65 years | 194 |
| ≥65 years | 1 |
| Sex: Female, Male(Participants) | All Participants (Lacosamide) |
|---|---|
| Female | 134 |
| Male | 105 |
| Race/Ethnicity, Customized(Participants) | All Participants (Lacosamide) |
|---|---|
| American Indian/Alaskan Native | 1 |
| Asian | 48 |
| Black | 4 |
| White | 178 |
| Other/Mixed | 8 |
| Race/Ethnicity, Customized(Participants) | All Participants (Lacosamide) |
|---|---|
| Hispanic or Latino | 28 |
| Not Hispanic or Latino | 211 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe, or global development is discontinued, and 18 months after trial completion. Investigators may request access to anonymized individual patient-level data and redacted trial documents which may include: analysis-ready datasets, study protocol, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a prespecified time, typically 12 months, on a password protected portal. This plan may change if the risk of re-identifying trial participants is determined to be too high after the trial is completed; in this case and to protect participants, individual patient-level data would not be made available.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe or global development is discontinued, and 18 months after trial completion.
Access criteria: Qualified researchers may request access to anonymized IPD and redacted study documents which may include: raw datasets, analysis-ready datasets, study protocol, blank case report form, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal.
Data sharing details ↗ · www.vivli.org
Ran from Aug 2015 to primary completion in Mar 2023, 91 months.
Results were first posted in Dec 2023, 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lacosamide
Epilepsy, Idiopathic Generalized →